1
|
Lévesque H, Viallard JF, Houivet E, Bonnotte B, Voisin S, Le Cam-Duchez V, Maillot F, Lambert M, Liozon E, Hervier B, Fain O, Guillet B, Schmidt J, Luca LE, Ebbo M, Ferreira-Maldent N, Babuty A, Sailler L, Duffau P, Barbay V, Audia S, Benichou J, Graveleau J, Benhamou Y. Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients. Thromb Res 2024; 237:79-87. [PMID: 38555718 DOI: 10.1016/j.thromres.2024.03.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 02/19/2024] [Accepted: 03/07/2024] [Indexed: 04/02/2024]
Abstract
BACKGROUND Acquired hemophilia A (AHA) is a rare autoimmune disorder due to autoantibodies against Factor VIII, with a high mortality risk. Treatments aim to control bleeding and eradicate antibodies by immunosuppression. International recommendations rely on registers and international expert panels. METHODS CREHA, an open-label randomized trial, compared the efficacy and safety of cyclophosphamide and rituximab in association with steroids in patients with newly diagnosed AHA. Participants were treated with 1 mg/kg prednisone daily and randomly assigned to receive either 1.5-2 mg/kg/day cyclophosphamide orally for 6 weeks, or 375 mg/m2 rituximab once weekly for 4 weeks. The primary endpoint was complete remission over 18 months. Secondary endpoints included time to achieve complete remission, relapse occurrence, mortality, infections and bleeding, and severe adverse events. RESULTS Recruitment was interrupted because of new treatment recommendations after 108 patients included (58 cyclophosphamide, 50 rituximab). After 18 months, 39 cyclophosphamide patients (67.2 %) and 31 rituximab patients (62.0 %) were in complete remission (OR 1.26; 95 % CI, 0.57 to 2.78). In the poor prognosis group (FVIII < 1 IU/dL, inhibitor titer > 20 BU mL-1), significantly more remissions were observed with cyclophosphamide (22 patients, 78.6 %) than with rituximab (12 patients, 48.0 %; p = 0.02). Relapse rates, deaths, severe infections, and bleeding were similar in the 2 groups. In patients with severe infection, cumulative doses of steroids were significantly higher than in patients without infection (p = 0.03). CONCLUSION Cyclophosphamide and rituximab showed similar efficacy and safety. As first line, cyclophosphamide seems preferable, especially in poor prognosis patients, as administered orally and less expensive. FUNDING French Ministry of Health. CLINICALTRIALS gov number: NCT01808911.
Collapse
Affiliation(s)
- H Lévesque
- Normandie Univ, UNIROUEN, U 1096, CHU Rouen, Department of Internal Medicine, F-76000 Rouen, France.
| | - J F Viallard
- Service de Médecine Interne et Maladies Infectieuses Hôpital Haut-Lévêque, CHU Bordeaux, 5 avenue de Magellan, 33604 Pessac, France
| | - E Houivet
- Department of Biostatistics, CHU Rouen, F-76031 Rouen, France
| | - B Bonnotte
- Service de médecine interne et immunologie clinique, CHU Dijon-Bourgogne, Université de Dijon, F-21079 Dijon, France
| | - S Voisin
- Department of Internal Medicine, CHU Toulouse, F-31059 Toulouse. France
| | - V Le Cam-Duchez
- Normandie Univ, UNIROUEN, Hématologie biologique, F-76031 Rouen, France
| | - F Maillot
- Département de Médecine Interne et immunologie clinique, CHRU Tours, Université de Tours, F-37044 Tours, France
| | - M Lambert
- CHU Lille, Département de Médecine Interne et d'Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares Nord et Nord-Ouest de France (CeRAINO), European Reerence Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNECT), F-59000 Lille, France
| | - E Liozon
- Department of Internal Medicine, Dupuytren Hospital, F-87000 Limoges, France
| | - B Hervier
- Service de Médecine Interne, Hôpital Saint-Louis, APHP, 75010 Paris & INSERM UMR-S 976, Human Immunology, Pathophysiology, Immunotherapy, Saint-Louis Research Institute, F-75000 Paris, France
| | - O Fain
- Sorbonne Université, APHP, Service de Médecine Interne-DMU i3, Hôpital Saint-Antoine, Paris F-75000, France
| | - B Guillet
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR-S 1085, F-35000 Rennes, France
| | - J Schmidt
- Department of Internal Medicine, Amiens University Hospital, F-80000 Amiens, France
| | - L E Luca
- Department of Internal Medicine, Poitiers University Hospital, F-86000 Poitiers, France
| | - M Ebbo
- Service de Médecine Interne, Hôpital La Timone, CHU Marseille, Aix-Marseille Université, F-13000 Marseille, France
| | - N Ferreira-Maldent
- Département de Médecine Interne et immunologie clinique, CHRU Tours, Université de Tours, F-37044 Tours, France
| | - A Babuty
- Service d'Hématologie Biologique, CRC-MHC, CHU de Nantes, Nantes Cedex 1, France
| | - L Sailler
- Department of Internal Medicine, CHU Toulouse, F-31059 Toulouse. France
| | - P Duffau
- Service de Médecine Interne-Immunologie Clinique Hôpital Saint-André, CHU Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France
| | - V Barbay
- Normandie Univ, UNIROUEN, Hématologie biologique, F-76031 Rouen, France
| | - S Audia
- Service de médecine interne et immunologie clinique, CHU Dijon-Bourgogne, Université de Dijon, F-21079 Dijon, France
| | - J Benichou
- Department of Biostatistics, CHU Rouen and CESP UMR 1018, University of Rouen and University Paris-Saclay, F-76031 Rouen, France
| | - J Graveleau
- Nantes Université, CHU Nantes, Service de Médecine Interne, Nantes, France
| | - Y Benhamou
- Normandie Univ, UNIROUEN, U 1096, CHU Rouen, Department of Internal Medicine, F-76000 Rouen, France
| |
Collapse
|
2
|
Dubois J, Tosato G, Garrigue P, Taieb D, Guillet B, Nail V. Short-Term Biological Toxicity Prediction of [ 177Lu]Lutetium-Oxodotreotide: An Original Retrospective Analysis. Cancer Biother Radiopharm 2024. [PMID: 38655905 DOI: 10.1089/cbr.2023.0195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/26/2024] Open
Abstract
Introduction: [177Lu]Lutetium (Lu)-oxodotreotide is a radiopharmaceutical drug used as peptide receptor radionuclide therapy (PRRT) for somatostatin receptor-expressing neuroendocrine neoplasms. It provides an additional effective alternative treatment for these rare cancers. Although well tolerated, its safety profile must continue to be characterized to support its use as a first-line treatment or for additional cycles. This study aims to evaluate factors associated with the occurrence of [177Lu]Lu-oxodotreotide induced short-term toxicity. Materials and Methods: A retrospective observational monocentric study was carried out from July 2013 to October 2021. Inclusion criteria were defined as follows: patients who received at least four cycles of [177Lu]Lu-oxodotreotide and were followed up for 6 months after the last injection. Graduated toxicity was defined using the National Cancer Institute Common Terminology Criteria for Adverse Events 5.0. Cox regression was used in the analysis. Results: Forty patients were included. The most frequent toxicities occurred during the first cycle and were graded as G1 or G2. As expected, toxicities were predominantly hematological and hepatic, with incomplete reversibility after each cycle. The following factors were significantly related to the occurrence of hematological or hepatic toxicity during PRRT: gastrointestinal primary tumor diagnosis, bone metastases, peritoneal metastases, pancreatic metastases or pulmonary metastases, and high tumor grade. Conclusion: Knowledge and consideration of these factors in adjusting [177Lu]Lu-oxodotreotide treatment regimen could help prevent or reduce the severity of these toxicities. Further studies are still warranted to refine these results and improve treatment management.
Collapse
Affiliation(s)
- Julien Dubois
- Department of Radiopharmacy, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France
- Department of Radiopharmacy, Montpellier University Hospital, Montpellier University, Montpellier, France
- Cancer Research Institute of Montpellier (IRCM), University of Montpellier, Montpellier, France
| | - Guillaume Tosato
- Montpellier University Hospital, Montpellier University, Montpellier, France
| | - Philippe Garrigue
- Department of Radiopharmacy, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France
| | - David Taieb
- Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France
| | - Benjamin Guillet
- Department of Radiopharmacy, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France
| | - Vincent Nail
- Department of Radiopharmacy, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France
| |
Collapse
|
3
|
Muller R, Cauchois R, Lagarde M, Roffino S, Genovesio C, Fernandez S, Hache G, Guillet B, Kara Y, Marlinge M, Lenting PJ, Poullin P, Dignat-George F, Tellier E, Kaplanski G. Mortality, cardiac and cerebral damages reduction by IL-1 inhibition in a murine model of TTP. Blood 2024:blood.2023021974. [PMID: 38598839 DOI: 10.1182/blood.2023021974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 02/09/2024] [Accepted: 03/09/2024] [Indexed: 04/12/2024] Open
Abstract
Thrombotic thrombocytopenic purpura (TTP), a rare but fatal disease if untreated, is due to alteration in Von Willebrand factor cleavage resulting in capillary microthrombi formation and ischemic organ damage. Interleukin-1 (IL-1), has been shown to drive sterile inflammation following ischemia and could play an essential contribution to post-ischemic organ damage in TTP. Our objectives were to evaluate IL-1 involvement during TTP and to test the efficacy of the recombinant IL-1 receptor antagonist, anakinra, in a murine TTP model. We retrospectively measured plasmatic IL-1 concentrations in TTP patients and controls. TTP patients exhibited elevated plasma IL-1α and β concentrations, which correlated with disease course and survival. In a TTP mouse model, we administered anakinra (IL-1 inhibitor) or placebo for 5 days and evaluated the efficacy of this treatment. Anakinra significantly reduced mortality of mice (P<0.001). Anakinra significantly decreased TTP-induced cardiac damages as assessed by blood troponin concentrations, evaluation of left ventricular function by echocardiography, [18F]FDG PET of myocardial glucose metabolism, and cardiac histology. Anakinra also significantly reduced brain TTP-induced damages, evaluated through blood PS100b concentrations, nuclear imaging and histology. We finally showed that IL-1α and β trigger endothelial degranulation in vitro, leading to the release of Von Willebrand factor. In conclusion, Anakinra significantly reduced TTP mortality in a pre-clinical model of the disease by inhibiting both endothelial degranulation and post-ischemic inflammation, supporting further evaluations in humans.
Collapse
Affiliation(s)
- Romain Muller
- French Reference Center for Thrombotic Microangiopathies, France
| | - Raphael Cauchois
- French Reference Center for Thrombotic Microangiopathies, France
| | - Marie Lagarde
- French Reference Center for Thrombotic Microangiopathies, France
| | - Sandrine Roffino
- Aix-Marseille University, CNRS, ISM Inst Movement Sci, Marseille, France, Marseille, France
| | | | | | - Guillaume Hache
- Aix-Marseille University, APHM, INSERM, INRAE, C2VN, CERIMED, CHU Timone, Biology department, Marseille, France, Marseille, France
| | | | - Yeter Kara
- Aix-Marseille University, INSERM, INRAE, C2VN, Marseille, France, Marseille, France
| | - Marion Marlinge
- Aix-Marseille University, APHM, INSERM, INRAE, C2VN, CERIMED, CHU Timone, Biology department, Marseille, France, Marseille, France
| | | | - Pascale Poullin
- 3. French Reference Center for Thrombotic Microangiopathies, France
| | | | - Edwige Tellier
- 2. French Reference Center for Thrombotic Microangiopathies, France
| | | |
Collapse
|
4
|
Albert NL, Garrigue P, Guillet B, Burger IA. Correction to: Highlights of the 35th EANM Annual Congress 2022, onsite edition in Barcelona, Spain: "FROM BARCELONA WITH LOVE". Eur J Nucl Med Mol Imaging 2023; 50:4114. [PMID: 37646835 DOI: 10.1007/s00259-023-06419-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Affiliation(s)
- Nathalie L Albert
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - Philippe Garrigue
- Aix‑Marseille Univ, APHM, C2VN, CERIMED, INSERM, INRAE, CNRS, Radiopharmacy, Marseille, France
| | - Benjamin Guillet
- Aix‑Marseille Univ, APHM, C2VN, CERIMED, INSERM, INRAE, CNRS, Radiopharmacy, Marseille, France
| | - Irene A Burger
- Department of Nuclear Medicine, Kantonsspital Baden, Baden, Switzerland.
- Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.
| |
Collapse
|
5
|
Albert NL, Garrigue P, Guillet B, Burger IA. Highlights of the 35th EANM Annual Congress 2022, onsite edition in Barcelona, Spain: "FROM BARCELONA WITH LOVE". Eur J Nucl Med Mol Imaging 2023; 50:3168-3176. [PMID: 37432447 DOI: 10.1007/s00259-023-06306-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/12/2023]
Affiliation(s)
- Nathalie L Albert
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - Philippe Garrigue
- Aix-Marseille Univ, APHM, C2VN, CERIMED, INSERM, INRAE, CNRS, Radiopharmacy, Marseille, France
| | - Benjamin Guillet
- Aix-Marseille Univ, APHM, C2VN, CERIMED, INSERM, INRAE, CNRS, Radiopharmacy, Marseille, France
| | - Irene A Burger
- Department of Nuclear Medicine, Kantonsspital Baden, Baden, Switzerland.
- Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.
| |
Collapse
|
6
|
Bobot M, Suissa L, Hak JF, Burtey S, Guillet B, Hache G. Kidney disease and stroke: epidemiology and potential mechanisms of susceptibility. Nephrol Dial Transplant 2023; 38:1940-1951. [PMID: 36754366 DOI: 10.1093/ndt/gfad029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Indexed: 02/10/2023] Open
Abstract
Patients with chronic kidney disease (CKD) have an increased risk of both ischaemic and haemorrhagic stroke compared with the general population. Both acute and chronic kidney impairment are independently associated with poor outcome after the onset of a stroke, after adjustment for confounders. End-stage kidney disease (ESKD) is associated with a 7- and 9-fold increased incidence of both ischaemic and haemorrhagic strokes, respectively, poorer neurological outcome and a 3-fold higher mortality. Acute kidney injury (AKI) occurs in 12% of patients with stroke and is associated with a 4-fold increased mortality and unfavourable functional outcome. CKD patients seem to have less access to revascularisation techniques like thrombolysis and thrombectomy despite their poorer prognosis. Even if CKD patients could benefit from these specific treatments in acute ischaemic stroke, their prognosis remains poor. After thrombolysis, CKD is associated with a 40% increased risk of intracerebral haemorrhage (ICH), a 20% increase in mortality and poorer functional neurological outcomes. After thrombectomy, CKD is not associated with ICH but is still associated with increased mortality, and AKI with unfavourable outcome and mortality. The beneficial impact of gliflozins on the prevention of stroke is still uncertain. Non-traditional risk factors of stroke, like uraemic toxins, can lead to chronic cerebrovascular disease predisposing to stroke in CKD, notably through an increase in the blood-brain barrier permeability and impaired coagulation and thrombosis mechanisms. Preclinical and clinical studies are needed to specifically assess the impact of these non-traditional risk factors on stroke incidence and outcomes, aiming to optimize and identify potential therapeutic targets.
Collapse
Affiliation(s)
- Mickaël Bobot
- Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, AP-HM, Marseille, France
- Aix-Marseille Université, INSERM 1263, INRAE 1260, C2VN, Marseille, France
- CERIMED, Aix Marseille Université, Marseille, France
| | - Laurent Suissa
- Aix-Marseille Université, INSERM 1263, INRAE 1260, C2VN, Marseille, France
- Unité Neurovasculaire/Stroke Center, Hôpital de la Timone, AP-HM, Marseille, France
| | - Jean-François Hak
- CERIMED, Aix Marseille Université, Marseille, France
- Service de Radiologie, Hôpital de la Timone, AP-HM, Marseille, France
| | - Stéphane Burtey
- Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, AP-HM, Marseille, France
- Aix-Marseille Université, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | - Benjamin Guillet
- Aix-Marseille Université, INSERM 1263, INRAE 1260, C2VN, Marseille, France
- CERIMED, Aix Marseille Université, Marseille, France
- Service de Radiopharmacie, AP-HM, Marseille, France
| | - Guillaume Hache
- Aix-Marseille Université, INSERM 1263, INRAE 1260, C2VN, Marseille, France
- CERIMED, Aix Marseille Université, Marseille, France
- Pharmacie, Hôpital de la Timone, AP-HM, Marseille, France
| |
Collapse
|
7
|
Louis B, Nail V, Nachar O, Bouhlel A, Moyon A, Balasse L, Simoncini S, Chabert A, Fernandez S, Brige P, Hache G, Tintaru A, Morgat C, Dignat-George F, Garrigue P, Guillet B. Design and preclinical evaluation of a novel apelin-based PET radiotracer targeting APJ receptor for molecular imaging of angiogenesis. Angiogenesis 2023; 26:463-475. [PMID: 36973482 PMCID: PMC10328853 DOI: 10.1007/s10456-023-09875-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Accepted: 03/17/2023] [Indexed: 03/29/2023]
Abstract
APJ has been extensively described in the pathophysiology of angiogenesis and cell proliferation. The prognostic value of APJ overexpression in many diseases is now established. This study aimed to design a PET radiotracer that specifically binds to APJ. Apelin-F13A-NODAGA (AP747) was synthesized and radiolabeled with gallium-68 ([68Ga]Ga-AP747). Radiolabeling purity was excellent (> 95%) and stable up to 2 h. Affinity constant of [67Ga]Ga-AP747 was measured on APJ-overexpressing colon adenocarcinoma cells and was in nanomolar range. Specificity of [68Ga]Ga-AP747 for APJ was evaluated in vitro by autoradiography and in vivo by small animal PET/CT in both colon adenocarcinoma mouse model and Matrigel plug mouse model. Dynamic of [68Ga]Ga-AP747 PET/CT biodistributions was realized on healthy mice and pigs for two hours, and quantification of signal in organs showed a suitable pharmacokinetic profile for PET imaging, largely excreted by urinary route. Matrigel mice and hindlimb ischemic mice were submitted to a 21-day longitudinal follow-up with [68Ga]Ga-AP747 and [68Ga]Ga-RGD2 small animal PET/CT. [68Ga]Ga-AP747 PET signal in Matrigel was significantly more intense than that of [68Ga]Ga-RGD2. Revascularization of the ischemic hind limb was followed by LASER Doppler. In the hindlimb, [68Ga]Ga-AP747 PET signal was more than twice higher than that of [68Ga]Ga-RGD2 on day 7, and significantly superior over the 21-day follow-up. A significant, positive correlation was found between the [68Ga]Ga-AP747 PET signal on day 7 and late hindlimb perfusion on day 21. We developed a new PET radiotracer that specifically binds to APJ, [68Ga]Ga-AP747 that showed more efficient imaging properties than the most clinically advanced tracer of angiogenesis, [68Ga]Ga-RGD2.
Collapse
Affiliation(s)
- Béatrice Louis
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France
| | - Vincent Nail
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France
- Assistance Publique - Hôpitaux de Marseille, Pôle Pharmacie, Radiopharmacie, Marseille, France
| | - Oriane Nachar
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France
- Assistance Publique - Hôpitaux de Marseille, Pôle Pharmacie, Radiopharmacie, Marseille, France
| | - Ahlem Bouhlel
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France
| | - Anaïs Moyon
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France
- Assistance Publique - Hôpitaux de Marseille, Pôle Pharmacie, Radiopharmacie, Marseille, France
| | - Laure Balasse
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France
| | | | | | | | - Pauline Brige
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France
- Aix Marseille Univ, LIIE, Marseille, France
| | - Guillaume Hache
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France
| | - Aura Tintaru
- Aix Marseille Univ, CNRS, CINaM, Marseille, France
| | - Clément Morgat
- Univ. Bordeaux, CNRS, INCIA, UMR 5287, 33000, Bordeaux, France
- Nuclear Medicine Department, University Hospital of Bordeaux, 33000, Bordeaux, France
| | | | - Philippe Garrigue
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France.
- Assistance Publique - Hôpitaux de Marseille, Pôle Pharmacie, Radiopharmacie, Marseille, France.
| | - Benjamin Guillet
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Aix Marseille Univ, CNRS, CERIMED, Marseille, France
- Assistance Publique - Hôpitaux de Marseille, Pôle Pharmacie, Radiopharmacie, Marseille, France
| |
Collapse
|
8
|
Abellan Lopez M, Hutter L, Pagin E, Vélier M, Véran J, Giraudo L, Dumoulin C, Arnaud L, Macagno N, Appay R, Daniel L, Guillet B, Balasse L, Caso H, Casanova D, Bertrand B, Dignat F, Hermant L, Riesterer H, Guillemot F, Sabatier F, Magalon J. In vivo efficacy proof of concept of a large-size bioprinted dermo-epidermal substitute for permanent wound coverage. Front Bioeng Biotechnol 2023; 11:1217655. [PMID: 37560537 PMCID: PMC10407941 DOI: 10.3389/fbioe.2023.1217655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Accepted: 07/06/2023] [Indexed: 08/11/2023] Open
Abstract
Introduction: An autologous split-thickness skin graft (STSG) is a standard treatment for coverage of full-thickness skin defects. However, this technique has two major drawbacks: the use of general anesthesia for skin harvesting and scar sequelae on the donor site. In order to reduce morbidity associated with STSG harvesting, researchers have developed autologous dermo-epidermal substitutes (DESs) using cell culture, tissue engineering, and, more recently, bioprinting approaches. This study assessed the manufacturing reliability and in vivo efficacy of a large-size good manufacturing practice (GMP)-compatible bio-printed human DES, named Poieskin®, for acute wound healing treatment. Methods: Two batches (40 cm2 each) of Poieskin® were produced, and their reliability and homogeneity were assessed using histological scoring. Immunosuppressed mice received either samples of Poieskin® (n = 8) or human STSG (n = 8) immediately after longitudinal acute full-thickness excision of size 1 × 1.5 cm, applied on the skeletal muscle plane. The engraftment rate was assessed through standardized photographs on day 16 of the follow-up. Moreover, wound contraction, superficial vascularization, and local inflammation were evaluated via standardized photographs, laser Doppler imaging, and PET imaging, respectively. Histological analysis was finally performed after euthanasia. Results: Histological scoring reached 75% ± 8% and 73% ± 12%, respectively, displaying a robust and homogeneous construct. Engraftment was comparable for both groups: 91.8% (SD = 0.1152) for the Poieskin® group versus 100% (SD = 0) for the human STSG group. We did not record differences in either graft perfusion, PET imaging, or histological scoring on day 16. Conclusion: Poieskin® presents consistent bioengineering manufacturing characteristics to treat full-thickness cutaneous defects as an alternative to STSG in clinical applications. Manufacturing of Poieskin® is reliable and homogeneous, leading to a clinically satisfying rate of graft take compared to the reference human STSG in a mouse model. These results encourage the use of Poieskin® in phase I clinical trials as its manufacturing procedure is compatible with pharmaceutical guidelines.
Collapse
Affiliation(s)
- Maxime Abellan Lopez
- Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
| | | | | | - Mélanie Vélier
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France
| | - Julie Véran
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France
| | - Laurent Giraudo
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France
| | - Chloe Dumoulin
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France
| | - Laurent Arnaud
- Vascular Biology Department, Hôpital de la Timone, AP-HM, Marseille, France
| | - Nicolas Macagno
- Anatomy and Pathology Department, INSERM U1263, C2VN, Hôpital de la Timone, Marseille, France
| | - Romain Appay
- Anatomy and Pathology Department, INSERM U1263, C2VN, Hôpital de la Timone, Marseille, France
| | - Laurent Daniel
- Anatomy and Pathology Department, INSERM U1263, C2VN, Hôpital de la Timone, Marseille, France
| | - Benjamin Guillet
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
- Centre Européen de Recherche en Imagerie Médicale (CERIMED), Aix-Marseille Université, Centre National de la Recherche Scientifique, Marseille, France
| | - Laure Balasse
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
| | - Hugo Caso
- Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France
| | - Dominique Casanova
- Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
| | - Baptiste Bertrand
- Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
| | - Françoise Dignat
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France
| | | | | | | | - Florence Sabatier
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France
| | - Jérémy Magalon
- Aix-Marseille Université, INSERM, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France
| |
Collapse
|
9
|
Benloucif A, Meyer D, Balasse L, Goubard A, Danner L, Bouhlel A, Castellano R, Guillet B, Chames P, Kerfelec B. Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies. Front Immunol 2023; 14:1200652. [PMID: 37388728 PMCID: PMC10303918 DOI: 10.3389/fimmu.2023.1200652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 05/25/2023] [Indexed: 07/01/2023] Open
Abstract
Introduction Mesothelin (MSLN) is overexpressed in a wide variety of cancers with few therapeutic options and has recently emerged as an attractive target for cancer therapy, with a large number of approaches currently under preclinical and clinical investigation. In this respect, developing mesothelin specific tracers as molecular companion tools for predicting patient eligibility, monitoring then response to mesothelin-targeting therapies, and tracking the evolution of the disease or for real-time visualisation of tumours during surgery is of growing importance. Methods We generated by phage display a nanobody (Nb S1) and used enzymatic approaches were used to site-directed conjugate Nb S1 with either ATTO 647N fluorochrome or NODAGA chelator for fluorescence and positron emission tomography imaging (PET) respectively. Results We demonstrated that Nb S1 displays a high apparent affinity and specificity for human mesothelin and demonstrated that the binding, although located in the membrane distal domain of mesothelin, is not impeded by the presence of MUC16, the only known ligand of mesothelin, nor by the therapeutic antibody amatuximab. In vivo experiments showed that both ATTO 647N and [68Ga]Ga-NODAGA-S1 rapidly and specifically accumulated in mesothelin positive tumours compared to mesothelin negative tumours or irrelevant Nb with a high tumour/background ratio. The ex vivo biodistribution profile analysis also confirmed a significantly higher uptake of Nb S1 in MSLN-positive tumours than in MSLNlow tumours. Conclusion We demonstrated for the first time the use of an anti-MSLN nanobody as PET radiotracer for same day imaging of MSLN+ tumours, targeting an epitope compatible with the monitoring of amatuximab-based therapies and current SS1-derived-drug conjugates.
Collapse
Affiliation(s)
- Abdennour Benloucif
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Damien Meyer
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Laure Balasse
- Aix Marseille Univ, CNRS, Centre Européen de Recherche en Imagerie Medicale (CERIMED), Marseille, France
- Aix-marseille University, INSERM, INRAE, Centre de recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
| | - Armelle Goubard
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, TrGET Preclinical Platform, Marseille, France
| | - Lucile Danner
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Ahlem Bouhlel
- Aix Marseille Univ, CNRS, Centre Européen de Recherche en Imagerie Medicale (CERIMED), Marseille, France
- Aix-marseille University, INSERM, INRAE, Centre de recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
| | - Rémy Castellano
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, TrGET Preclinical Platform, Marseille, France
| | - Benjamin Guillet
- Aix Marseille Univ, CNRS, Centre Européen de Recherche en Imagerie Medicale (CERIMED), Marseille, France
- Aix-marseille University, INSERM, INRAE, Centre de recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
| | - Patrick Chames
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Brigitte Kerfelec
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| |
Collapse
|
10
|
Kiss OC, Scott PJH, Behe M, Penuelas I, Passchier J, Rey A, Patt M, Aime S, Jalilian A, Laverman P, Cheng Z, Chauvet AF, Engle J, Cleeren F, Zhu H, Vercouillie J, van Dam M, Zhang MR, Perk L, Guillet B, Alves F. Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharm Chem 2023; 8:6. [PMID: 36952073 PMCID: PMC10036721 DOI: 10.1186/s41181-023-00192-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Accepted: 03/15/2023] [Indexed: 03/24/2023] Open
Abstract
BACKGROUND The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. MAIN BODY This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals. CONCLUSION Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field, and include new PET-labelling methods for 11C and 18F, the importance of choosing the proper chelator for a given radioactive metal ion, implications of total body PET on use of radiopharmaceuticals, legislation issues and radionuclide therapy including the emerging role of 161Tb.
Collapse
Affiliation(s)
- Oliver C Kiss
- Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany.
| | | | - Martin Behe
- Paul Scherrer Institute, Villigen, Switzerland
| | | | | | - Ana Rey
- Universidad de la Rebublica, Montevideo, Uruguay
| | | | | | | | - Peter Laverman
- Radboud University Medical Center, Nijmegen, The Netherlands
| | - Zhen Cheng
- Shanghai Institute of Materia Medica, Shanghai, China
| | | | | | | | - Hua Zhu
- Peking University Cancer Hospital, Beijing, China
| | | | | | | | - Lars Perk
- Radboud University Medical Center, Nijmegen, The Netherlands
| | | | | |
Collapse
|
11
|
Joshkon A, Tabouret E, Traboulsi W, Bachelier R, Simoncini S, Roffino S, Jiguet-Jiglaire C, Badran B, Guillet B, Foucault-Bertaud A, Leroyer AS, Dignat-George F, Chinot O, Fayyad-Kazan H, Bardin N, Blot-Chabaud M. Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma. Acta Neuropathol Commun 2022; 10:151. [PMID: 36274147 PMCID: PMC9590138 DOI: 10.1186/s40478-022-01451-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 09/28/2022] [Indexed: 11/17/2022] Open
Abstract
Rationale Glioblastoma multiforme (GBM) is a primary brain tumor with poor prognosis. The U.S. food and drug administration approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this treatment is frequent and fails to enhance the overall survival of patients. In this study, we aimed to identify novel mechanism(s) responsible for bevacizumab-resistance in CD146-positive glioblastoma. Methods The study was performed using sera from GBM patients and human GBM cell lines in culture or xenografted in nude mice. Results We found that an increase in sCD146 concentration in sera of GBM patients after the first cycle of bevacizumab treatment was significantly associated with poor progression free survival and shorter overall survival. Accordingly, in vitro treatment of CD146-positive glioblastoma cells with bevacizumab led to a high sCD146 secretion, inducing cell invasion. These effects were mediated through integrin αvβ3 and were blocked by mucizumab, a novel humanized anti-sCD146 antibody. In vivo, the combination of bevacizumab with mucizumab impeded CD146 + glioblastoma growth and reduced tumor cell dissemination to an extent significantly higher than that observed with bevacizumab alone. Conclusion We propose sCD146 to be 1/ an early biomarker to predict and 2/ a potential target to prevent bevacizumab resistance in patients with glioblastoma. Supplementary Information The online version contains supplementary material available at 10.1186/s40478-022-01451-3.
Collapse
|
12
|
Lévesque H, Guillet B, Benhamou Y. [Acquired hemophilia and pregnancy: A necessarily multidisciplinary approach]. Rev Med Interne 2022; 43:494-497. [PMID: 35637030 DOI: 10.1016/j.revmed.2022.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Revised: 03/22/2022] [Accepted: 04/02/2022] [Indexed: 11/19/2022]
Abstract
The occurrence of acquired hemophilia during pregnancy or postpartum is rare (2 to 10 % in series). It is generally suspected in the presence of haemorrhagic manifestations (especially subcutataneous or mucosal bleeding) associated with an isolated prolongation of the activated partial thromboplastin time (APTT). The diagnosis is confirmed by the association of a low level of factor VIII (FVIII) and the presence of an anti-FVIII inhibitor. Postpartum management is similar to that of other acquired haemophilias: correction of a severe haemorrhagic syndrome by "bypassing" agents, eradication of the inhibitor by corticosteroids alone or in combination with another immunosuppressive agent depending on the residual level of FVIII and the titer of the inhibitor. Management of the forms occurring during pregnancy is based on rare experiences or expert opinions. The management of childbirth is particularly delicate in terms of haemorrhage, especially if the anti-FVIII inhibitor is still present, and must be prepared in a multidisciplinary manner. Finally, as with any acquired hemophilia, a relapse is possible, especially in the year following remission. During a subsequent pregnancy, the risk of recurrence is possible but should not be a contraindication to a new pregnancy.
Collapse
Affiliation(s)
- H Lévesque
- Service de médecine interne, Normandie université, UNIROUEN, Interne, 76031 Rouen, France.
| | - B Guillet
- Centre de traitement des maladies hémorragiques, CHU de Rennes, Rennes, France; Inserm, EHESP, IRSET (institut de recherche en santé, environnement et travail) - UMR_S 1085, Université Rennes, CHU de Rennes, 35000 Rennes, France
| | - Y Benhamou
- Service de médecine interne, Normandie université, UNIROUEN, Interne, 76031 Rouen, France
| |
Collapse
|
13
|
Bernardes E, Caravan P, van Dam RM, Deuther-Conrad W, Ellis B, Furumoto S, Guillet B, Huang YY, Jia H, Laverman P, Li Z, Liu Z, Lodi F, Miao Y, Perk L, Schirrmacher R, Vercoullie J, Yang H, Yang M, Yang X, Zhang J, Zhang MR, Zhu H. Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharm Chem 2022; 7:9. [PMID: 35471681 PMCID: PMC9043146 DOI: 10.1186/s41181-022-00162-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Accepted: 02/15/2022] [Indexed: 11/22/2022] Open
Abstract
Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
Results This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals and also a contribution in relation to MRI-agents is included. Conclusion Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
Collapse
Affiliation(s)
| | - Peter Caravan
- Massuchusetts General Hospital, Harvard University, Cambridge, USA
| | | | - Winnie Deuther-Conrad
- Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Leipzig, Germany. .,Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
| | - Beverley Ellis
- Manchester University NHS Foundation Trust, Manchester, UK
| | | | | | - Ya-Yao Huang
- National Taiwan University College of Medicine, Taipei, Taiwan
| | | | | | | | | | | | | | - Lars Perk
- Radboud University Medical Center, Nijmegen, The Netherlands
| | | | | | | | - Min Yang
- Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, People's Republic of China
| | - Xing Yang
- Peking University First Hospital, Beijing, China
| | | | | | - Hua Zhu
- Peking University Cancer Hospital, Beijing, China
| |
Collapse
|
14
|
Nollet M, Bachelier R, Joshkon A, Traboulsi W, Mahieux A, Moyon A, Muller A, Somasundaram I, Simoncini S, Peiretti F, Leroyer AS, Guillet B, Granel B, Dignat-George F, Bardin N, Foucault-Bertaud A, Blot-Chabaud M. Multiple variants of soluble CD146 are involved in Systemic Sclerosis: identification of a novel pro-fibrotic factor. Arthritis Rheumatol 2022; 74:1027-1038. [PMID: 35001552 DOI: 10.1002/art.42063] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 11/19/2021] [Accepted: 01/04/2022] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Systemic sclerosis (SSc) is an autoimmune disorder characterized by excessive fibrosis, immune dysfunction and vascular damages, in which expression of many growth factors is deregulated. CD146 was recently described as a major actor in SSc. As CD146 also exists as a circulating soluble form (sCD146) acting as a growth factor in numerous angiogenic- and inflammatory-related pathologies, we sought to identify the mechanisms underlying the generation of sCD146 and characterized the regulation and functions of the different identified variants in SSc. METHODS To this end, we performed in vitro experiments, including RNA-seq and antibody arrays, and in vivo experiments using animal models of SSc induced by bleomycin and of hindlimb ischemia. RESULTS Multiple forms of sCD146, generated by both shedding and alternative splicing of the primary transcript, were discovered. The shed form of sCD146 was generated from the cleavage of both long and short membrane isoforms of membrane CD146 through Adam10 and Tace metalloproteinases, respectively. In addition, two novel sCD146 splice variants, I5-13-sCD146 and I10-sCD146 were identified. Of interest, I5-13-sCD146 was significantly increased in sera of SSc patients, in particular in patients with pulmonary fibrosis, whereas I10-sCD146 was decreased. Further experiments revealed that shed sCD146 and I10-sCD146 displayed pro-angiogenic activity through FAK and PKCε signalling pathways, respectively, whereas I5-13-sCD146 displayed pro-fibrotic effects through wint1/β-catenin/wisp1 pathway. CONCLUSION Variants of sCD146, and in particular the novel I5-13-sCD146 splice variant, could thus constitute novel biomarkers and/or molecular targets for the diagnosis and treatment of SSc, but also of other angiogenesis- or fibrosis-related pathologies.
Collapse
Affiliation(s)
- Marie Nollet
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | - Richard Bachelier
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | - Ahmad Joshkon
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | - Waël Traboulsi
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | - Amandine Mahieux
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | - Anais Moyon
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France.,CERIMED, Aix-Marseille University, Marseille, France
| | - Alexandre Muller
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | - Indumathi Somasundaram
- Department of Stem Cell and Regenerative Medicine, D.Y. Patil University, Kolhapur, India
| | | | - Franck Peiretti
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | - Aurélie S Leroyer
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | - Benjamin Guillet
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France.,CERIMED, Aix-Marseille University, Marseille, France
| | - Brigitte Granel
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France.,Internal Medicine Department, AP-HM, Marseille, France
| | | | - Nathalie Bardin
- Aix-Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France
| | | | | |
Collapse
|
15
|
Giraud R, Moyon A, Simoncini S, Duchez AC, Nail V, Chareyre C, Bouhlel A, Balasse L, Fernandez S, Vallier L, Hache G, Sabatier F, Dignat-George F, Lacroix R, Guillet B, Garrigue P. Tracking Radiolabeled Endothelial Microvesicles Predicts Their Therapeutic Efficacy: A Proof-of-Concept Study in Peripheral Ischemia Mouse Model Using SPECT/CT Imaging. Pharmaceutics 2022; 14:pharmaceutics14010121. [PMID: 35057018 PMCID: PMC8778059 DOI: 10.3390/pharmaceutics14010121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 12/24/2021] [Accepted: 12/29/2021] [Indexed: 11/16/2022] Open
Abstract
Microvesicles, so-called endothelial large extracellular vesicles (LEVs), are of great interest as biological markers and cell-free biotherapies in cardiovascular and oncologic diseases. However, their therapeutic perspectives remain limited due to the lack of reliable data regarding their systemic biodistribution after intravenous administration. Methods: Applied to a mouse model of peripheral ischemia, radiolabeled endothelial LEVs were tracked and their in vivo whole-body distribution was quantified by microSPECT/CT imaging. Hindlimb perfusion was followed by LASER Doppler and motility impairment function was evaluated up to day 28 post-ischemia. Results: Early and specific homing of LEVs to ischemic hind limbs was quantified on the day of ischemia and positively correlated with reperfusion intensity at a later stage on day 28 after ischemia, associated with an improved motility function. Conclusions: This concept is a major asset for investigating the biodistribution of LEVs issued from other cell types, including cancer, thus partly contributing to better knowledge and understanding of their fate after injection.
Collapse
Affiliation(s)
- Romain Giraud
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
- CERIMED, CNRS, Marseille, Aix Marseille University, 13385 Marseille, France; (V.N.); (S.F.)
- Radiopharmacy, Pôle Pharmacie, University Hospitals of Marseille, APHM, 13005 Marseille, France
| | - Anaïs Moyon
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
- CERIMED, CNRS, Marseille, Aix Marseille University, 13385 Marseille, France; (V.N.); (S.F.)
- Radiopharmacy, Pôle Pharmacie, University Hospitals of Marseille, APHM, 13005 Marseille, France
| | - Stéphanie Simoncini
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
| | - Anne-Claire Duchez
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
| | - Vincent Nail
- CERIMED, CNRS, Marseille, Aix Marseille University, 13385 Marseille, France; (V.N.); (S.F.)
- Radiopharmacy, Pôle Pharmacie, University Hospitals of Marseille, APHM, 13005 Marseille, France
| | - Corinne Chareyre
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
| | - Ahlem Bouhlel
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
- CERIMED, CNRS, Marseille, Aix Marseille University, 13385 Marseille, France; (V.N.); (S.F.)
| | - Laure Balasse
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
- CERIMED, CNRS, Marseille, Aix Marseille University, 13385 Marseille, France; (V.N.); (S.F.)
| | - Samantha Fernandez
- CERIMED, CNRS, Marseille, Aix Marseille University, 13385 Marseille, France; (V.N.); (S.F.)
| | - Loris Vallier
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
| | - Guillaume Hache
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
- CERIMED, CNRS, Marseille, Aix Marseille University, 13385 Marseille, France; (V.N.); (S.F.)
| | - Florence Sabatier
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
| | - Françoise Dignat-George
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
- Department of Hematology and Vascular Biology, University Hospitals of Marseille, APHM, 13005 Marseille, France
| | - Romaric Lacroix
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
- Department of Hematology and Vascular Biology, University Hospitals of Marseille, APHM, 13005 Marseille, France
| | - Benjamin Guillet
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
- CERIMED, CNRS, Marseille, Aix Marseille University, 13385 Marseille, France; (V.N.); (S.F.)
- Radiopharmacy, Pôle Pharmacie, University Hospitals of Marseille, APHM, 13005 Marseille, France
| | - Philippe Garrigue
- C2VN, INSERM, INRAE, Aix Marseille University, 13385 Marseille, France; (R.G.); (A.M.); (S.S.); (A.-C.D.); (C.C.); (A.B.); (L.B.); (L.V.); (G.H.); (F.S.); (F.D.-G.); (R.L.); (B.G.)
- CERIMED, CNRS, Marseille, Aix Marseille University, 13385 Marseille, France; (V.N.); (S.F.)
- Radiopharmacy, Pôle Pharmacie, University Hospitals of Marseille, APHM, 13005 Marseille, France
- Correspondence:
| |
Collapse
|
16
|
Moyon A, Garrigue P, Fernandez S, Hubert F, Balasse L, Brige P, Hache G, Nail V, Blot-Chabaud M, Dignat-George F, Rochais F, Guillet B. Comparison of a New 68Ga-Radiolabelled PET Imaging Agent sCD146 and RGD Peptide for In Vivo Evaluation of Angiogenesis in Mouse Model of Myocardial Infarction. Cells 2021; 10:cells10092305. [PMID: 34571954 PMCID: PMC8466330 DOI: 10.3390/cells10092305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 08/31/2021] [Accepted: 08/31/2021] [Indexed: 11/16/2022] Open
Abstract
Ischemic vascular diseases are associated with elevated tissue expression of angiomotin (AMOT), a promising molecular target for PET imaging. On that basis, we developed an AMOT-targeting radiotracer, 68Ga-sCD146 and performed the first in vivo evaluation on a myocardial infarction mice model and then, compared AMOT expression and αvβ3-integrin expression with 68Ga-sCD146 and 68Ga-RGD2 imaging. After myocardial infarction (MI) induced by permanent ligation of the left anterior descending coronary artery, myocardial perfusion was evaluated by Doppler ultrasound and by 18F-FDG PET imaging. 68Ga-sCD146 and 68Ga-RGD2 PET imaging were performed. In myocardial infarction model, heart-to-muscle ratio of 68Ga-sCD146 imaging showed a significantly higher radiotracer uptake in the infarcted area of MI animals than in sham (* p = 0.04). Interestingly, we also observed significant correlations between 68Ga-sCD146 imaging and delayed residual perfusion assessed by 18F-FDG (* p = 0.04), with lowest tissue fibrosis assessed by histological staining (* p = 0.04) and with functional recovery assessed by ultrasound imaging (** p = 0.01). 68Ga-sCD146 demonstrated an increase in AMOT expression after MI. Altogether, significant correlations of early post-ischemic 68Ga-sCD146 uptake with late heart perfusion, lower tissue fibrosis and better functional recovery, make 68Ga-sCD146 a promising radiotracer for tissue angiogenesis assessment after MI.
Collapse
Affiliation(s)
- Anaïs Moyon
- Pharmacological Faculty, Aix Marseille University, INSERM 1263, INRAE 1260, C2VN, 13385 Marseille, France; (P.G.); (G.H.); (V.N.); (M.B.-C.); (F.D.-G.); (B.G.)
- Medical Faculty, Aix-Marseille University, CNRS 2012, CERIMED, 13385 Marseille, France; (S.F.); (L.B.); (P.B.)
- APHM, Service de Radiopharmacie, 13005 Marseille, France
- Correspondence:
| | - Philippe Garrigue
- Pharmacological Faculty, Aix Marseille University, INSERM 1263, INRAE 1260, C2VN, 13385 Marseille, France; (P.G.); (G.H.); (V.N.); (M.B.-C.); (F.D.-G.); (B.G.)
- Medical Faculty, Aix-Marseille University, CNRS 2012, CERIMED, 13385 Marseille, France; (S.F.); (L.B.); (P.B.)
- APHM, Service de Radiopharmacie, 13005 Marseille, France
| | - Samantha Fernandez
- Medical Faculty, Aix-Marseille University, CNRS 2012, CERIMED, 13385 Marseille, France; (S.F.); (L.B.); (P.B.)
| | - Fabien Hubert
- Medical Faculty, Aix Marseille University, INSERM, MMG, U 1251, 13385 Marseille, France; (F.H.); (F.R.)
| | - Laure Balasse
- Medical Faculty, Aix-Marseille University, CNRS 2012, CERIMED, 13385 Marseille, France; (S.F.); (L.B.); (P.B.)
| | - Pauline Brige
- Medical Faculty, Aix-Marseille University, CNRS 2012, CERIMED, 13385 Marseille, France; (S.F.); (L.B.); (P.B.)
- Medical Faculty, Aix-Marseille University, UR4264, LIIE, 13385 Marseille, France
| | - Guillaume Hache
- Pharmacological Faculty, Aix Marseille University, INSERM 1263, INRAE 1260, C2VN, 13385 Marseille, France; (P.G.); (G.H.); (V.N.); (M.B.-C.); (F.D.-G.); (B.G.)
- Medical Faculty, Aix-Marseille University, CNRS 2012, CERIMED, 13385 Marseille, France; (S.F.); (L.B.); (P.B.)
| | - Vincent Nail
- Pharmacological Faculty, Aix Marseille University, INSERM 1263, INRAE 1260, C2VN, 13385 Marseille, France; (P.G.); (G.H.); (V.N.); (M.B.-C.); (F.D.-G.); (B.G.)
- Medical Faculty, Aix-Marseille University, CNRS 2012, CERIMED, 13385 Marseille, France; (S.F.); (L.B.); (P.B.)
- APHM, Service de Radiopharmacie, 13005 Marseille, France
| | - Marcel Blot-Chabaud
- Pharmacological Faculty, Aix Marseille University, INSERM 1263, INRAE 1260, C2VN, 13385 Marseille, France; (P.G.); (G.H.); (V.N.); (M.B.-C.); (F.D.-G.); (B.G.)
| | - Françoise Dignat-George
- Pharmacological Faculty, Aix Marseille University, INSERM 1263, INRAE 1260, C2VN, 13385 Marseille, France; (P.G.); (G.H.); (V.N.); (M.B.-C.); (F.D.-G.); (B.G.)
- APHM, Service d’Hématologie, Hôpital Conception, 13005 Marseille, France
| | - Francesca Rochais
- Medical Faculty, Aix Marseille University, INSERM, MMG, U 1251, 13385 Marseille, France; (F.H.); (F.R.)
| | - Benjamin Guillet
- Pharmacological Faculty, Aix Marseille University, INSERM 1263, INRAE 1260, C2VN, 13385 Marseille, France; (P.G.); (G.H.); (V.N.); (M.B.-C.); (F.D.-G.); (B.G.)
- Medical Faculty, Aix-Marseille University, CNRS 2012, CERIMED, 13385 Marseille, France; (S.F.); (L.B.); (P.B.)
- APHM, Service de Radiopharmacie, 13005 Marseille, France
| |
Collapse
|
17
|
Garrigue P, Mounien L, Champion S, Mouhajir Y, Pechere L, Guillet B, Landrier JF, Seree E. Long-term administration of resveratrol at low doses improves neurocognitive performance as well as cerebral blood flow and modulates the inflammatory pathways in the brain. J Nutr Biochem 2021; 97:108786. [PMID: 34082127 DOI: 10.1016/j.jnutbio.2021.108786] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Revised: 03/15/2021] [Accepted: 05/14/2021] [Indexed: 01/24/2023]
Abstract
There is an increasing prevalence of coincident cerebrovascular deficiency and cognitive dysfunction with aging. Increased oxidative stress as well as inflammation that occurs with aging are associated with the impairment of cerebral vascularization. Interestingly, Resveratrol (RSV), a natural phytoalexin, is known to be a strong antioxidant and possesses anti-inflammatory properties. Collectively, these observations strongly suggest that RSV could protect against cerebral vascularization defect and then improves the decline cognitive function associated with aging. In order to test this hypothesis, we investigated the effect of a long-term RSV treatment (1.25 mg/day for 5 months) on cognitive performances of animals that we have allowed to age normally. Then, we further analyzed the gene expression profile and the cerebral blood flow in the brain. By means of novel object recognition (NOR) test, we observed that RSV enhanced NOR performances of aged rats. In addition, RSV enhanced cerebral blood flow during NOR task in aged rats. Using microarrays experiments, we also showed that several pathways related to inflammation and oxidative stress (Eicosanoid signaling, MIF-mediated innate immunity, NF-kB signaling, TNFR2 signaling, IL6 signaling, Production of nitric oxide and ROS) were down-regulated in the brain of RSV treatments rats compared to control rats. In conclusion, these results support that a long-term treatment with RSV improves cognitive performance in the elderly male rat model. This effect is associated with an increase in cerebral blood flow and a decrease in the expression of several pro-inflammatory pathways in the brain.
Collapse
Affiliation(s)
- Philippe Garrigue
- Aix Marseille Univ, INSERM, INRAE, C2VN, 13005 Marseille, France; Aix-Marseille Univ, Centre Européen de Recherche en Imagerie Médicale (CERIMED), 13005 Marseille, France
| | - Lourdes Mounien
- Aix Marseille Univ, INSERM, INRAE, C2VN, 13005 Marseille, France
| | | | - Yassin Mouhajir
- Aix Marseille Univ, INSERM, INRAE, C2VN, 13005 Marseille, France
| | | | - Benjamin Guillet
- Aix Marseille Univ, INSERM, INRAE, C2VN, 13005 Marseille, France; Aix-Marseille Univ, Centre Européen de Recherche en Imagerie Médicale (CERIMED), 13005 Marseille, France
| | | | - Eric Seree
- Aix Marseille Univ, INSERM, INRAE, C2VN, 13005 Marseille, France.
| |
Collapse
|
18
|
Bobot M, Hache G, Moyon A, Fernandez S, Balasse L, Daniel L, Garrigue P, Brige P, Chopinet S, Dignat-George F, Brunet P, Burtey S, Guillet B. Renal SPECT/CT with 99mTc-dimercaptosuccinic acid is a non-invasive predictive marker for the development of interstitial fibrosis in a rat model of renal insufficiency. Nephrol Dial Transplant 2021; 36:804-810. [PMID: 33367913 DOI: 10.1093/ndt/gfaa374] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Chronic kidney disease (CKD) increases cardiovascular risk and mortality. Renal fibrosis plays a major role in the progression of CKD but, to date, histology remains the gold standard to assess fibrosis. Non-invasive techniques are needed to assess renal parenchymal impairment and to perform the longitudinal evaluation of renal structure. Thus we evaluated renal isotopic imaging by single-photon emission computed tomography/computed tomography (SPECT/CT) with technetium-99m (99mTc)-dimercaptosuccinic acid (DMSA) to monitor renal impairment during renal insufficiency in rats. METHODS Renal insufficiency was induced by an adenine-rich diet (ARD) at 0.25 and 0.5% for 28 days. Renal dysfunction was evaluated by assaying biochemical markers and renal histology. Renal parenchymal impairment was assessed by SPECT/CT isotopic imaging with 99mTc-DMSA on Days 0, 7, 14, 21, 28, 35 and 49. RESULTS Compared with controls, ARD rats developed renal dysfunction characterized by increased serum creatinine and blood urea nitrogen, fibrosis and tubulointerstitial damage in the kidneys, with a dose-dependent effect of the adenine concentration. 99mTc-DMSA SPECT-CT imaging showed a significant decrease in renal uptake over time in 0.25 and 0.5% ARD rats compared with control rats (P = 0.011 and P = 0.0004, respectively). 99mTc-DMSA uptake on Day 28 was significantly inversely correlated with Sirius red staining evaluated on Day 49 (r = 0.89, P < 0.0001, R2 = 0.67). CONCLUSIONS 99mTc-DMSA renal scintigraphy allows a longitudinal follow-up of risk of renal fibrosis in rats. We found that the reduction of renal parenchyma in ARD rats is inversely proportional to newly formed fibrous tissue in the kidney. Our results suggest that 99mTc-DMSA renal scintigraphy may be a useful non-invasive prognostic marker of the development of renal fibrosis in animals and should be tested in humans.
Collapse
Affiliation(s)
- Mickaël Bobot
- Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France.,Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille Université, Marseille, France.,C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Université, Marseille, France
| | - Guillaume Hache
- Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille Université, Marseille, France.,C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Université, Marseille, France.,Pharmacie, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Anaïs Moyon
- Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille Université, Marseille, France.,C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Université, Marseille, France.,Service de Radiopharmacie, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Samantha Fernandez
- Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille Université, Marseille, France
| | - Laure Balasse
- Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille Université, Marseille, France
| | - Laurent Daniel
- C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Université, Marseille, France.,Laboratoire d'Anatomopathologie, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Philippe Garrigue
- Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille Université, Marseille, France.,C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Université, Marseille, France.,Service de Radiopharmacie, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Pauline Brige
- Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille Université, Marseille, France.,Laboratoire d'Imagerie Interventionnelle Expérimentale, EA, 4264, Aix Marseille Université, Marseille, France
| | - Sophie Chopinet
- Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille Université, Marseille, France.,Laboratoire d'Imagerie Interventionnelle Expérimentale, EA, 4264, Aix Marseille Université, Marseille, France.,Service de Chirurgie Digestive, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | | | - Philippe Brunet
- Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France.,C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Université, Marseille, France
| | - Stéphane Burtey
- Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France.,C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Université, Marseille, France
| | - Benjamin Guillet
- Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille Université, Marseille, France.,C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Université, Marseille, France.,Service de Radiopharmacie, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| |
Collapse
|
19
|
Metwally K, Bastiancich C, Correard F, Novell A, Fernandez S, Guillet B, Larrat B, Mensah S, Estève MA, Da Silva A. Development of a multi-functional preclinical device for the treatment of glioblastoma. Biomed Opt Express 2021; 12:2264-2279. [PMID: 33996228 PMCID: PMC8086436 DOI: 10.1364/boe.419412] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 03/11/2021] [Accepted: 03/12/2021] [Indexed: 05/18/2023]
Abstract
Glioblastoma multiforme (GBM) is one of the most common and aggressive malignant primary brain tumors in adults. The treatment of GBM is limited by the blood-brain barrier (BBB), which limits the diffusion of appropriate concentrations of therapeutic agents at the tumor site. Among experimental therapies, photo-thermal therapy (PTT) mediated by nanoparticles is a promising strategy. To propose a preclinical versatile research instrument for the development of new PTT for GBM, a multipurpose integrated preclinical device was developed. The setup is able to perform: i) BBB permeabilization by focused ultrasound sonication (FUS); ii) PTT with continuous wave laser; iii) in situ temperature monitoring with photo-acoustic (PA) measurements. In vivo preliminary subcutaneous and transcranial experiments were conducted on healthy or tumor-bearing mice. Transcranial FUS-induced BBB permeabilization was validated using single photon emission computed tomography (SPECT) imaging. PTT capacities were monitored by PA thermometry, and are illustrated through subcutaneous and transcranial in vivo experiments. The results show the therapeutic possibilities and ergonomy of such integrated device as a tool for the validation of future treatments.
Collapse
Affiliation(s)
- Khaled Metwally
- Aix Marseille Univ, CNRS, Centrale Marseille, Institut Fresnel, Marseille, France
- Aix Marseille Univ, CNRS, Centrale Marseille, LMA, Marseille, France
- Contributed equally to this work
| | - Chiara Bastiancich
- Aix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
- Contributed equally to this work
| | - Florian Correard
- Aix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
- APHM, Hôpital de la Timone, Service Pharmacie, Marseille, France
| | - Anthony Novell
- Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, Orsay, France
| | - Samantha Fernandez
- Aix-Marseille Univ, Centre Européen de Recherche en Imagerie Médicale (CERIMED), Marseille, France
| | - Benjamin Guillet
- Aix-Marseille Univ, Centre Européen de Recherche en Imagerie Médicale (CERIMED), Marseille, France
- Aix-Marseille Univ, INSERM, INRA, Center de Recherche en Cardiovasculaire et Nutrition (C2VN), Marseille, France
| | - Benoit Larrat
- Univ. Paris Saclay, CNRS, CEA, DRF/JOLIOT/NEUROSPIN/BAOBAB, Gif-sur-Yvette, France
| | - Serge Mensah
- Aix Marseille Univ, CNRS, Centrale Marseille, LMA, Marseille, France
| | - Marie-Anne Estève
- Aix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
- APHM, Hôpital de la Timone, Service Pharmacie, Marseille, France
| | - Anabela Da Silva
- Aix Marseille Univ, CNRS, Centrale Marseille, Institut Fresnel, Marseille, France
| |
Collapse
|
20
|
Nail V, Moyon A, Nachar O, Gabriel S, Guillet B, Garrigue P. Pharmaceutical interviews to overcome digestive artefacts on [ 99m Tc]Tc-tetrofosmin myocardial perfusion scintigraphy. J Clin Pharm Ther 2021; 46:1480-1483. [PMID: 33754343 DOI: 10.1111/jcpt.13418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 03/05/2021] [Accepted: 03/12/2021] [Indexed: 11/30/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVES Poor image quality was randomly seen in [99m Tc]Tc-tetrofosmin myocardial perfusion scintigraphic imaging. The interference hampered or even precluded medical interpretation. Our objective was to identify the cause of the random interferences. METHODS Out of 40 patients planned for [99m Tc]Tc-tetrofosmin MPS, 36 presented normal tracer uptake and 4 exhibited subdiaphragmatic artefacts. Pharmaceutical interviews (P.I.) were set up to formally identify aetiologies of subdiaphragmatic uptake of [99m Tc]Tc-tetrofosmin. Patients were questioned about their diet and current drug treatments. RESULTS AND DISCUSSION P.I. led to identification of dipyridamole as the cause of the artefacts. The systematic ingestion of a solid 25-gram high-fat snack bar and a glass of fresh water was introduced immediately after the injection of dipyridamole in 12 other patients undergoing [99m Tc]Tc-tetrofosmin MPS. None of the 12 patients presented subdiaphragmatic artefacts. WHAT IS NEW AND CONCLUSION P.I. identified the cause of poor scintigraphic images to allow improved diagnoses.
Collapse
Affiliation(s)
- Vincent Nail
- Radiopharmacie, Hôpital Nord, APHM, INSERM 1263, INRAE 1260, C2VN, CERIMED, Aix-Marseille Univ, Marseille, France
| | - Anaïs Moyon
- Radiopharmacie, Hôpital Nord, APHM, INSERM 1263, INRAE 1260, C2VN, CERIMED, Aix-Marseille Univ, Marseille, France
| | - Oriane Nachar
- Radiopharmacie, Hôpital Nord, APHM, INSERM 1263, INRAE 1260, C2VN, CERIMED, Aix-Marseille Univ, Marseille, France
| | - Sophie Gabriel
- NSERM 1263, INRAE 1260, C2VN, CNRS 2012, CERIMED,, Aix-Marseille Univ, Marseille, France
| | - Benjamin Guillet
- Radiopharmacie, Hôpital Nord, APHM, INSERM 1263, INRAE 1260, C2VN, CERIMED, Aix-Marseille Univ, Marseille, France
| | - Philippe Garrigue
- Radiopharmacie, Hôpital Nord, APHM, INSERM 1263, INRAE 1260, C2VN, CERIMED, Aix-Marseille Univ, Marseille, France
| |
Collapse
|
21
|
Diop A, Diop A, Hak JF, Di Bisceglie M, Bartoli JM, Guillet B, Vidal V. Hemostatic embolization of renal artery pseudoaneurysm using absorbable surgical suture (FairEmbo concept). Diagn Interv Imaging 2020; 101:757-758. [DOI: 10.1016/j.diii.2020.04.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 04/07/2020] [Indexed: 12/25/2022]
|
22
|
Di Bisceglie M, Hak JF, Diop AD, Salazar G, Brige P, Panneau J, Tradi F, Habert P, Campion JY, Diop AN, Soulez G, Guillet B, Vidal V. FairEmbo Concept for Arterial Embolizations: In Vivo Feasibility and Safety Study with Suture-Based Microparticles Compared with Microspheres. Cardiovasc Intervent Radiol 2020; 44:625-632. [PMID: 33099701 DOI: 10.1007/s00270-020-02678-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2020] [Accepted: 10/03/2020] [Indexed: 12/30/2022]
Abstract
PURPOSE Microspheres are effective embolic agents, especially for the management of bleeding and oncologic lesions. The first FairEmbo study reported the effectiveness of embolization using suture fragments. The effectiveness and safety of arterial embolization with suture-based microparticles (SBM) were assessed in a swine model. MATERIALS AND METHODS In this ethical-approved animal study, a polar artery in each kidney was embolized in four swine: one side with hand-cut non-absorbable SBM (Flexocrin 2®) and the contralateral side with Embozene® 900 for comparison. Swine were followed for 3 months (M3) to evaluate the effectiveness and the safety of SBM. Follow-up protocol included clinical monitoring, computed tomography (CT) control and digital subtraction angiography (DSA), followed by histological analyses. The SBM confection parameters were evaluated by automatic microscopic sizer. RStudio software and Mann-Whitney test (significance at P < 0.05) were used for statistics. RESULTS The average size of SBM was 1002 μm (SD = 258). All targets were effectively embolized by SBM with an angiogram defect estimated at 45.6% (95% CI [35.9-55.2]), compared to 40.5% (95% CI [30.6-55.5]) for Embozene® group (P = 0.342). The average duration of SBM embolization procedure was significantly increased compared to Embozene® embolization (1202 s versus 222 s, P = 0.029). There were no statistical differences in M3 DSA and CT for SBM and Embozene®, with persistence of partial arterial occlusion and atrophic embolized area. No postoperative complications were observed on clinical and CT controls. CONCLUSION This experimental study suggests that embolization with SBM is feasible, safe and effective in short- and medium-term follow-up as compared to microspheres.
Collapse
Affiliation(s)
- Mathieu Di Bisceglie
- Interventional Radiololy Section, Department of Medical Imaging, University Hospital Timone, APHM, Marseille, France.
- LiiE, Aix Marseille University, Marseille, France.
- CERIMED, Aix Marseille University, 27 Bd Jean Moulin 13005, Marseille, France.
| | - Jean-Francois Hak
- Interventional Radiololy Section, Department of Medical Imaging, University Hospital Timone, APHM, Marseille, France
- LiiE, Aix Marseille University, Marseille, France
- CERIMED, Aix Marseille University, 27 Bd Jean Moulin 13005, Marseille, France
| | - Abdoulaye Dione Diop
- Diagnostic and Medical Imaging Center, Fann National University Hospital Center, 5035, Dakar, Senegal
| | - Gloria Salazar
- Division of Interventional Radiology, Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Pauline Brige
- LiiE, Aix Marseille University, Marseille, France
- CERIMED, Aix Marseille University, 27 Bd Jean Moulin 13005, Marseille, France
| | - Julien Panneau
- Interventional Radiololy Section, Department of Medical Imaging, University Hospital Timone, APHM, Marseille, France
- LiiE, Aix Marseille University, Marseille, France
- CERIMED, Aix Marseille University, 27 Bd Jean Moulin 13005, Marseille, France
| | - Farouk Tradi
- Interventional Radiololy Section, Department of Medical Imaging, University Hospital Timone, APHM, Marseille, France
- LiiE, Aix Marseille University, Marseille, France
- CERIMED, Aix Marseille University, 27 Bd Jean Moulin 13005, Marseille, France
- Department of Radiology, University Hospital Center of Montreal, Montreal, Canada
| | - Paul Habert
- Interventional Radiololy Section, Department of Medical Imaging, University Hospital Timone, APHM, Marseille, France
- LiiE, Aix Marseille University, Marseille, France
- CERIMED, Aix Marseille University, 27 Bd Jean Moulin 13005, Marseille, France
| | | | | | - Gilles Soulez
- Department of Radiology, University Hospital Center of Montreal, Montreal, Canada
| | - Benjamin Guillet
- CERIMED, Aix Marseille University, 27 Bd Jean Moulin 13005, Marseille, France
- INSERM1263, INRA 1260, C2VN, Aix Marseille University, Marseille, France
- Department of Radiopharmacy, APHM, Marseille, France
| | - Vincent Vidal
- Interventional Radiololy Section, Department of Medical Imaging, University Hospital Timone, APHM, Marseille, France
- LiiE, Aix Marseille University, Marseille, France
- CERIMED, Aix Marseille University, 27 Bd Jean Moulin 13005, Marseille, France
| |
Collapse
|
23
|
Fanelli R, Chastel A, Previti S, Hindié E, Vimont D, Zanotti-Fregonara P, Fernandez P, Garrigue P, Lamare F, Schollhammer R, Balasse L, Guillet B, Rémond E, Morgat C, Cavelier F. Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging. Bioconjug Chem 2020; 31:2339-2349. [DOI: 10.1021/acs.bioconjchem.0c00419] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Roberto Fanelli
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| | - Adrien Chastel
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Santo Previti
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| | - Elif Hindié
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Delphine Vimont
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
| | | | - Philippe Fernandez
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Philippe Garrigue
- Aix-Marseille University, INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Marseille 13385, France
- Aix-Marseille University, Centre Européen de Recherche en Imagerie Médicale, Marseille 13005, France
| | - Frédéric Lamare
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Romain Schollhammer
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Laure Balasse
- Aix-Marseille University, INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Marseille 13385, France
| | - Benjamin Guillet
- Aix-Marseille University, INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Marseille 13385, France
- Aix-Marseille University, Centre Européen de Recherche en Imagerie Médicale, Marseille 13005, France
| | - Emmanuelle Rémond
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| | - Clément Morgat
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Florine Cavelier
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| |
Collapse
|
24
|
Ding L, Lyu Z, Louis B, Tintaru A, Laurini E, Marson D, Zhang M, Shao W, Jiang Y, Bouhlel A, Balasse L, Garrigue P, Mas E, Giorgio S, Iovanna J, Huang Y, Pricl S, Guillet B, Peng L. Surface Charge of Supramolecular Nanosystems for In Vivo Biodistribution: A MicroSPECT/CT Imaging Study. Small 2020; 16:e2003290. [PMID: 32794645 DOI: 10.1002/smll.202003290] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 06/29/2020] [Indexed: 06/11/2023]
Abstract
Bioimaging has revolutionized medicine by providing accurate information for disease diagnosis and treatment. Nanotechnology-based bioimaging is expected to further improve imaging sensitivity and specificity. In this context, supramolecular nanosystems based on self-assembly of amphiphilic dendrimers for single photon emission computed tomography (SPECT) bioimaging are developed. These dendrimers bear multiple In3+ radionuclides at their terminals as SPECT reporters. By replacing the macrocyclic 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid cage with the smaller 1,4,7-triazacyclononane-1,4,7-triacetic acid scaffold as the In3+ chelator, the corresponding dendrimer exhibits neutral In3+ -complex terminals in place of negatively charged In3+ -complex terminals. This negative-to-neutral surface charge alteration completely reverses the zeta-potential of the nanosystems from negative to positive. As a consequence, the resulting SPECT nanoprobe generates a highly sought-after biodistribution profile accompanied by a drastically reduced uptake in liver, leading to significantly improved tumor imaging. This finding contrasts with current literature reporting that positively charged nanoparticles have preferential accumulation in the liver. As such, this study provides new perspectives for improving the biodistribution of positively charged nanosystems for biomedical applications.
Collapse
Affiliation(s)
- Ling Ding
- Aix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325, Equipe Labellisée Ligue Contre le Cancer, Marseille, 13288, France
- Aix-Marseille Université, CNRS, Centre de Résonance Magnétique Biologique et Médicale (CRMBM), UMR 7339, Marseille, 13385, France
| | - Zhenbin Lyu
- Aix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325, Equipe Labellisée Ligue Contre le Cancer, Marseille, 13288, France
- Aix Marseille Univ, CNRS, Institut de Chimie Radicalaire, UMR 7273, Marseille, 13013, France
| | - Beatrice Louis
- Aix-Marseille Université, INSERM, INRAE, C2VN, Marseille, 13005, France
- Aix-Marseille Université, CNRS, CERIMED, Marseille, 13005, France
| | - Aura Tintaru
- Aix Marseille Univ, CNRS, Institut de Chimie Radicalaire, UMR 7273, Marseille, 13013, France
| | - Erik Laurini
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, University of Trieste, Trieste, 34127, Italy
| | - Domenico Marson
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, University of Trieste, Trieste, 34127, Italy
| | - Mengjie Zhang
- School of Life Science, Advanced Research Institute of Multidisciplinary Science, Institute of Engineering Medicine, Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, 100081, China
| | - Wanxuan Shao
- School of Life Science, Advanced Research Institute of Multidisciplinary Science, Institute of Engineering Medicine, Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, 100081, China
| | - Yifan Jiang
- Aix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325, Equipe Labellisée Ligue Contre le Cancer, Marseille, 13288, France
| | - Ahlem Bouhlel
- Aix-Marseille Université, INSERM, INRAE, C2VN, Marseille, 13005, France
- Aix-Marseille Université, CNRS, CERIMED, Marseille, 13005, France
| | - Laure Balasse
- Aix-Marseille Université, INSERM, INRAE, C2VN, Marseille, 13005, France
- Aix-Marseille Université, CNRS, CERIMED, Marseille, 13005, France
| | - Philippe Garrigue
- Aix-Marseille Université, INSERM, INRAE, C2VN, Marseille, 13005, France
- Aix-Marseille Université, CNRS, CERIMED, Marseille, 13005, France
| | - Eric Mas
- Aix-Marseille Université, INSERM, CNRS, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, 13288, France
| | - Suzanne Giorgio
- Aix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325, Equipe Labellisée Ligue Contre le Cancer, Marseille, 13288, France
| | - Juan Iovanna
- Aix-Marseille Université, INSERM, CNRS, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, 13288, France
| | - Yuanyu Huang
- School of Life Science, Advanced Research Institute of Multidisciplinary Science, Institute of Engineering Medicine, Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, 100081, China
| | - Sabrina Pricl
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, University of Trieste, Trieste, 34127, Italy
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, 90-236, Poland
| | - Benjamin Guillet
- Aix-Marseille Université, INSERM, INRAE, C2VN, Marseille, 13005, France
- Aix-Marseille Université, CNRS, CERIMED, Marseille, 13005, France
| | - Ling Peng
- Aix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325, Equipe Labellisée Ligue Contre le Cancer, Marseille, 13288, France
| |
Collapse
|
25
|
Bobot M, Thomas L, Moyon A, Fernandez S, McKay N, Balasse L, Garrigue P, Brige P, Chopinet S, Poitevin S, Cérini C, Brunet P, Dignat-George F, Burtey S, Guillet B, Hache G. Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction. J Am Soc Nephrol 2020; 31:1509-1521. [PMID: 32527975 DOI: 10.1681/asn.2019070728] [Citation(s) in RCA: 65] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Accepted: 03/30/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Uremic toxicity may play a role in the elevated risk of developing cognitive impairment found among patients with CKD. Some uremic toxins, like indoxyl sulfate, are agonists of the transcription factor aryl hydrocarbon receptor (AhR), which is widely expressed in the central nervous system and which we previously identified as the receptor of indoxyl sulfate in endothelial cells. METHODS To characterize involvement of uremic toxins in cerebral and neurobehavioral abnormalities in three rat models of CKD, we induced CKD in rats by an adenine-rich diet or by 5/6 nephrectomy; we also used AhR-/- knockout mice overloaded with indoxyl sulfate in drinking water. We assessed neurologic deficits by neurobehavioral tests and blood-brain barrier disruption by SPECT/CT imaging after injection of 99mTc-DTPA, an imaging marker of blood-brain barrier permeability. RESULTS In CKD rats, we found cognitive impairment in the novel object recognition test, the object location task, and social memory tests and an increase of blood-brain barrier permeability associated with renal dysfunction. We found a significant correlation between 99mTc-DTPA content in brain and both the discrimination index in the novel object recognition test and indoxyl sulfate concentrations in serum. When we added indoxyl sulfate to the drinking water of rats fed an adenine-rich diet, we found an increase in indoxyl sulfate concentrations in serum associated with a stronger impairment in cognition and a higher permeability of the blood-brain barrier. In addition, non-CKD AhR-/- knockout mice were protected against indoxyl sulfate-induced blood-brain barrier disruption and cognitive impairment. CONCLUSIONS AhR activation by indoxyl sulfate, a uremic toxin, leads to blood-brain barrier disruption associated with cognitive impairment in animal models of CKD.
Collapse
Affiliation(s)
- Mickaël Bobot
- Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistnce Publique - Hôpitaux de Marseille, Marseille, France .,Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France.,Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France
| | - Laurent Thomas
- Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France.,Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France
| | - Anaïs Moyon
- Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France.,Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France.,Service de Radiopharmacie, Assistnce Publique - Hôpitaux de Marseille, Marseille, France
| | - Samantha Fernandez
- Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France
| | - Nathalie McKay
- Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France
| | - Laure Balasse
- Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France
| | - Philippe Garrigue
- Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France.,Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France.,Service de Radiopharmacie, Assistnce Publique - Hôpitaux de Marseille, Marseille, France
| | - Pauline Brige
- Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France.,Laboratoire d'Imagerie Interventionelle Expérimentale, Aix-Marseille Université, Marseille, France
| | - Sophie Chopinet
- Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France.,Laboratoire d'Imagerie Interventionelle Expérimentale, Aix-Marseille Université, Marseille, France.,Service de Chirurgie générale et transplantation hépatique, Hôpital de la Timone, Assistnce Publique - Hôpitaux de Marseille, Marseille, France
| | - Stéphane Poitevin
- Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France
| | - Claire Cérini
- Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France
| | - Philippe Brunet
- Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistnce Publique - Hôpitaux de Marseille, Marseille, France.,Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France
| | - Françoise Dignat-George
- Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France
| | - Stéphane Burtey
- Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistnce Publique - Hôpitaux de Marseille, Marseille, France.,Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France
| | - Benjamin Guillet
- Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France.,Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France.,Service de Radiopharmacie, Assistnce Publique - Hôpitaux de Marseille, Marseille, France
| | - Guillaume Hache
- Centre Européen de recherche en Imagerie Médicale, Aix Marseille Université, Centre National de la Recherche Scientifique, Marseille, France .,Centre de Recherche en Cardiovasculaireet Nutrition, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France.,Pharmacie, Hôpital de la Timone, Assistnce Publique - Hôpitaux de Marseille, Marseille, France
| |
Collapse
|
26
|
Di Bisceglie M, Hak J, Brige P, Tradi F, Bartoli J, Jacquier A, Moulin G, Guillet B, Vidal V. Abstract No. 404 Safety and efficacy of arterial embolization with permanent suture micro particles: the FAIR-Embo concept. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
27
|
Curti C, Mathias F, Savelli M, Garrigue P, Lamy E, Guillet B, Vanelle P. Carbidopa Capsules for Insulinoma Diagnostic: Compounding and Stability Study. Pharmaceutical Technology in Hospital Pharmacy 2020. [DOI: 10.1515/pthp-2019-0013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
AbstractBackgroundCarbidopa is a drug mainly used to treat Parkinson’s disease. Associations with levodopa or with levodopa/entacapone are commercialized, but there is no oral formulation of carbidopa alone available in Europe. As carbidopa can also be used as premedication of adult patients for insulinoma diagnosis, it must be compounded as single dose mg capsules. The single dose administration of a magistral preparation implies the compounding of only one capsule, or the loss of consequent quantities of active pharmaceutical ingredient. As an alternative solution, carbidopa capsules could be compounded as batches of hospital preparation.MethodWith this objective, a stability-indicating dosing method for 200 mg carbidopa capsules was developed. Then, the compounding process was assessed according to the European Pharmacopeia requirements. Finally, the stability of carbidopa capsules stored protected from light at room temperature was studied for one year.Results200 mg carbidopa capsules compounding process was validated on three independent batches. The beyond use date was fixed at one year.ConclusionOur work confirms that carbidopa 200 mg capsules can be realized in hospital pharmacy and its stability allows the compounding of large batches.
Collapse
Affiliation(s)
- Christophe Curti
- Service central de la qualité et de l’information pharmaceutiques (SCQIP), Assistance Publique Hopitaux de Marseille, Hôpital de la Conception, 147 boulevard Baille, Marseille13005, France
| | - Fanny Mathias
- Aix-Marseille Univ, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Equipe de Pharmaco-Chimie Radicalaire, Marseille, France
| | - Morane Savelli
- Service central de la qualité et de l’information pharmaceutiques (SCQIP), AP-HM, Marseille, France
| | - Philippe Garrigue
- INSERM, INSERM UMR_S1076 VRCM Aix-Marseille Université, France APHM, Hôpital La Timone, Service de Radiopharmacie, Marseille, France
- CERIMED, Aix-Marseille Université, Marseille, France
| | - Edouard Lamy
- Service central de la qualité et de l’information pharmaceutiques (SCQIP), AP-HM, Marseille, France
| | - Benjamin Guillet
- INSERM, INSERM UMR_S1076 VRCM Aix-Marseille Université, France APHM, Hôpital La Timone, Service de Radiopharmacie, Marseille, France
- CERIMED, Aix-Marseille Université, Marseille, France
| | - Patrice Vanelle
- Service central de la qualité et de l’information pharmaceutiques (SCQIP), AP-HM, hôpital de la Conception, 147 boulevard Baille, 13005Marseille, France
| |
Collapse
|
28
|
Stalin J, Traboulsi W, Vivancos-Stalin L, Nollet M, Joshkon A, Bachelier R, Guillet B, Lacroix R, Foucault-Bertaud A, Leroyer AS, Dignat-George F, Bardin N, Blot-Chabaud M. Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors. Int J Cancer 2020; 147:1666-1679. [PMID: 32022257 DOI: 10.1002/ijc.32909] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 12/20/2019] [Accepted: 01/22/2020] [Indexed: 12/17/2022]
Abstract
Initially discovered in human melanoma, CD146/MCAM is expressed on many tumors and is correlated with cancer progression and metastasis. However, targeting CD146 remains challenging since it is also expressed on other cell types, as vessel cells, where it displays important physiological functions. We previously demonstrated that CD146 is shed as a soluble form (sCD146) that vectorizes the effects of membrane CD146 on tumor angiogenesis, growth and survival. We thus generated a novel monoclonal antibody, the M2J-1 mAb, which specifically targets sCD146, but not membrane CD146, and counteracts these effects. In our study, we analyzed the effects of sCD146 on the dissemination and the associated procoagulant phenotype in two highly invasive human CD146-positive cancer cell lines (ovarian and melanoma). Results show that sCD146 induced epithelial to mesenchymal transition, favored the generation of cancer stem cells and increased the membrane expression of tissue factor. Treatment of cancer cells with sCD146 in two experimental models (subcutaneous xenografting and intracardiac injection of cancer cells in nude mice) led to increased tumor dissemination and procoagulant activity. The M2J-1 mAb drastically reduced metastasis but also procoagulant activity, in particular by decreasing the number of circulating tumor microparticles, and blocked the relevant signaling pathways as demonstrated by RNA expression profiling experiments. Thus, our findings demonstrate that sCD146 mediates important pro-metastatic and procoagulant effects in two CD146-positive tumors. Targeting sCD146 with the newly generated M2J-1 mAb could constitute an innovative strategy for preventing dissemination and thromboembolism in many CD146-positive tumors.
Collapse
Affiliation(s)
- Jimmy Stalin
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France
| | - Wael Traboulsi
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France
| | | | - Marie Nollet
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France
| | - Ahmad Joshkon
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France
| | - Richard Bachelier
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France
| | - Benjamin Guillet
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France.,CERIMED (European Center of Research in Medical Imaging), Aix-Marseille University, Marseille, France
| | - Romaric Lacroix
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France.,AP-HM, La Conception Hospital, Marseille, France
| | | | - Aurélie S Leroyer
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France
| | - Françoise Dignat-George
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France.,AP-HM, La Conception Hospital, Marseille, France
| | - Nathalie Bardin
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France.,AP-HM, La Conception Hospital, Marseille, France
| | - Marcel Blot-Chabaud
- INSERM, INRAE, C2VN, UFR Pharmacie, Aix-Marseille University, Marseille, France
| |
Collapse
|
29
|
Ding L, Lyu Z, Tintaru A, Laurini E, Marson D, Louis B, Bouhlel A, Balasse L, Fernandez S, Garrigue P, Mas E, Giorgio S, Pricl S, Guillet B, Peng L. A self-assembling amphiphilic dendrimer nanotracer for SPECT imaging. Chem Commun (Camb) 2020; 56:301-304. [DOI: 10.1039/c9cc07750b] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
An amphiphilic dendrimer bearing SPECT imaging reporters is self-assembled into supramolecular nanomicelles for effective tumor imaging.
Collapse
Affiliation(s)
- Ling Ding
- Aix Marseille Univ
- CNRS
- Centre Interdisciplinaire de Nanoscience de Marseille (UMR 7325)
- Equipe Labellisée Ligue Contre le Cancer
- Marseille
| | - Zhenbin Lyu
- Aix Marseille Univ
- CNRS
- Centre Interdisciplinaire de Nanoscience de Marseille (UMR 7325)
- Equipe Labellisée Ligue Contre le Cancer
- Marseille
| | - Aura Tintaru
- Aix Marseille Univ
- CNRS
- Institut de Chimie Radicalaire (UMR7273)
- Marseille
- France
| | - Erik Laurini
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS)
- DEA
- University of Trieste
- Trieste
- Italy
| | - Domenico Marson
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS)
- DEA
- University of Trieste
- Trieste
- Italy
| | | | | | | | | | | | - Eric Mas
- Aix Marseille Univ
- CNRS
- INSERM
- Institut Paoli-Calmettes
- Centre de Recherche en Cancérologie de Marseille (CRCM)
| | - Suzanne Giorgio
- Aix Marseille Univ
- CNRS
- Centre Interdisciplinaire de Nanoscience de Marseille (UMR 7325)
- Equipe Labellisée Ligue Contre le Cancer
- Marseille
| | - Sabrina Pricl
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS)
- DEA
- University of Trieste
- Trieste
- Italy
| | | | - Ling Peng
- Aix Marseille Univ
- CNRS
- Centre Interdisciplinaire de Nanoscience de Marseille (UMR 7325)
- Equipe Labellisée Ligue Contre le Cancer
- Marseille
| |
Collapse
|
30
|
Bobot M, Hache G, Fernandez S, Balasse L, Brige P, Chopinet S, Thomas L, Mckay N, Burtey S, Guillet B. L’atteinte cognitive est associée à une rupture de la barrière hémato-encéphalique et aux concentrations d’indoxyl sulfate dans deux modèles de maladie rénale chronique chez le rat. Nephrol Ther 2019. [DOI: 10.1016/j.nephro.2019.07.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Fersing C, Bouhlel A, Cantelli C, Garrigue P, Lisowski V, Guillet B. A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [ 18F]fluoride: Will [ 18F]AlF Replace 68Ga for Metal Chelate Labeling? Molecules 2019; 24:molecules24162866. [PMID: 31394799 PMCID: PMC6719958 DOI: 10.3390/molecules24162866] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 07/31/2019] [Accepted: 08/06/2019] [Indexed: 12/20/2022] Open
Abstract
Due to its ideal physical properties, fluorine-18 turns out to be a key radionuclide for positron emission tomography (PET) imaging, for both preclinical and clinical applications. However, usual biomolecules radiofluorination procedures require the formation of covalent bonds with fluorinated prosthetic groups. This drawback makes radiofluorination impractical for routine radiolabeling, gallium-68 appearing to be much more convenient for the labeling of chelator-bearing PET probes. In response to this limitation, a recent expansion of the 18F chemical toolbox gave aluminum [18F]fluoride chemistry a real prominence since the late 2000s. This approach is based on the formation of an [18F][AlF]2+ cation, complexed with a 9-membered cyclic chelator such as NOTA, NODA or their analogs. Allowing a one-step radiofluorination in an aqueous medium, this technique combines fluorine-18 and non-covalent radiolabeling with the advantage of being very easy to implement. Since its first reports, [18F]AlF radiolabeling approach has been applied to a wide variety of potential PET imaging vectors, whether of peptidic, proteic, or small molecule structure. Most of these [18F]AlF-labeled tracers showed promising preclinical results and have reached the clinical evaluation stage for some of them. The aim of this report is to provide a comprehensive overview of [18F]AlF labeling applications through a description of the various [18F]AlF-labeled conjugates, from their radiosynthesis to their evaluation as PET imaging agents.
Collapse
Affiliation(s)
- Cyril Fersing
- Institut de Recherche en Cancérologie de Montpellier (IRCM), University of Montpellier, INSERM U1194, Montpellier Cancer Institute (ICM), 34298 Montpellier, France.
- Nuclear Medicine Department, Montpellier Cancer Institute (ICM), University of Montpellier, 208 Avenue des Apothicaires, 34298 Montpellier CEDEX 5, France.
| | - Ahlem Bouhlel
- CERIMED, Aix-Marseille University, 13005 Marseille, France
- Centre de recherche en CardioVasculaire et Nutrition (C2VN), Aix-Marseille University, INSERM 1263, INRA 1260, 13385 Marseille, France
| | - Christophe Cantelli
- Institut de Recherche en Cancérologie de Montpellier (IRCM), University of Montpellier, INSERM U1194, Montpellier Cancer Institute (ICM), 34298 Montpellier, France
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, 34093 Montpellier CEDEX, France
| | - Philippe Garrigue
- CERIMED, Aix-Marseille University, 13005 Marseille, France
- Centre de recherche en CardioVasculaire et Nutrition (C2VN), Aix-Marseille University, INSERM 1263, INRA 1260, 13385 Marseille, France
- Department of Nuclear Medicine, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13385 Marseille, France
| | - Vincent Lisowski
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, 34093 Montpellier CEDEX, France
| | - Benjamin Guillet
- CERIMED, Aix-Marseille University, 13005 Marseille, France
- Centre de recherche en CardioVasculaire et Nutrition (C2VN), Aix-Marseille University, INSERM 1263, INRA 1260, 13385 Marseille, France
- Department of Nuclear Medicine, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13385 Marseille, France
| |
Collapse
|
32
|
Franceschini E, Balasse L, Roffino S, Guillet B. Probing the Cellular Size Distribution in Cell Samples Undergoing Cell Death. Ultrasound Med Biol 2019; 45:1787-1798. [PMID: 31023498 DOI: 10.1016/j.ultrasmedbio.2019.01.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 01/06/2019] [Accepted: 01/07/2019] [Indexed: 06/09/2023]
Abstract
A polydisperse scattering model adapted for concentrated medium, namely the polydisperse structure factor model, was examined to explain the backscatter coefficients (BSCs) measured from packed cell samples undergoing cell death. Cell samples were scanned using high-frequency ultrasound in the 10-42 MHz bandwidth. A parameter estimation procedure was proposed to estimate the volume fraction and the relative impedance contrast that could explain the changes in BSC pattern by considering the actual change in cellular size distribution. Quantitative ultrasound parameters were estimated and related to the percentage of dead cells determined by flow cytometry. The standard deviation of scatterer size distribution extracted from the polydisperse structure factor model and the spectral intercept were found to be strongly correlated to the percentage of dead cells (r2 = 0.79 and r2 = 0.72, respectively). This study contributes to the understanding of ultrasonic scattering from cells undergoing cell death toward the monitoring of cancer therapy.
Collapse
Affiliation(s)
| | - Laure Balasse
- Aix-Marseille Université, INSERM, INRA, C2 VN, Marseille, France
| | - Sandrine Roffino
- Aix-Marseille Université, CNRS, ISM, Marseille, France; Université Côte d'Azur, Nice, France
| | - Benjamin Guillet
- Aix-Marseille Université, INSERM, INRA, C2 VN, Marseille, France
| |
Collapse
|
33
|
Martin T, Moyon A, Fersing C, Terrier E, Gouillet A, Giraud F, Guillet B, Garrigue P. Have you looked for "stranger things" in your automated PET dose dispensing system? A process and operators qualification scheme. EJNMMI Radiopharm Chem 2019; 4:11. [PMID: 31659501 PMCID: PMC6565780 DOI: 10.1186/s41181-019-0061-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Accepted: 05/24/2019] [Indexed: 11/10/2022] Open
Abstract
Background Many nuclear medicine departments have equipped themselves with automated dispensing systems (ADS) for PET radiopharmaceuticals, in both the operators’ and the patients’ interests. Whether partially or fully automated, to date there is no marketed ADS representing a true “closed-system”. Despite the sterile, injectable nature of ready-to-use radiopharmaceutical drug solutions manipulated by these systems, neither manufacturer’s recommendation nor literature report was found about specific qualification of the process’ sterility, or about operators’ qualification on these dispensing systems. We set up a master plan validation in a radiopharmacy equipped with Trasis Unidose®, including: 1) monthly process-simulating media-fill tests and microbiological contamination assessments of the ADS surfaces; 2) initial and periodic qualification of the operators. The microbiological qualification consisted in surface biocontamination assessment on critical zones with Tryptic-Soy agar. The operator qualification consisted in the evaluation of the operators’ knowledge and skills for using the ADS. Results This study highlighted a minor, handborne microbiological contamination on our first assessment, that corrective actions solved. We therefore decided to brief our operators once a month on microbiological control results, hygiene and good practices, with the support of the present case illustrating the biodecontamination efficiency. Conclusions As the automation of PET monodose conditioning process still implies human intervention for material preparation and manual biodecontamination, this study illustrates that initial and periodic qualification of the environment and the conditioning process of ADS, including microbiological qualification and operators’ qualification, are needed to meet specifications.
Collapse
Affiliation(s)
| | - Anaïs Moyon
- Radiopharmacie Hôpital Timone AP-HM, Marseille, France.,CERIMED, CNRS 2012, Aix-Marseille Université, Marseille, France.,C2VN, INRA 1260, INSERM 1263, Aix-Marseille Université, Marseille, France
| | - Cyril Fersing
- Radiopharmacie Hôpital Nord AP-HM, Marseille, France
| | - Evan Terrier
- Radiopharmacie Hôpital Nord AP-HM, Marseille, France
| | - Aude Gouillet
- Radiopharmacie Hôpital Nord AP-HM, Marseille, France
| | | | - Benjamin Guillet
- Radiopharmacie Hôpital Nord AP-HM, Marseille, France.,CERIMED, CNRS 2012, Aix-Marseille Université, Marseille, France.,C2VN, INRA 1260, INSERM 1263, Aix-Marseille Université, Marseille, France
| | - Philippe Garrigue
- Radiopharmacie Hôpital Nord AP-HM, Marseille, France. .,CERIMED, CNRS 2012, Aix-Marseille Université, Marseille, France. .,C2VN, INRA 1260, INSERM 1263, Aix-Marseille Université, Marseille, France.
| |
Collapse
|
34
|
Bobot M, Hache G, Fernandez S, Balasse L, Brige P, Chopinet S, Thomas L, Mckay N, Burtey S, Guillet B. FO029COGNITIVE IMPAIRMENT WAS ASSOCIATED WITH BRAIN-BLOOD BARRIER PERMEABILITY IN TWO MODELS OF CHRONIC KIDNEY DISEASE IN RATS. Nephrol Dial Transplant 2019. [DOI: 10.1093/ndt/gfz107.fo029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Mickaël Bobot
- La Timone (Aix-Marseille Université), Marseille, France
| | | | - Samatha Fernandez
- Faculté de Médecine Timone (Aix-Marseille University), Marseille, France
| | - Laure Balasse
- Faculté de Médecine Timone (Aix-Marseille University), Marseille, France
| | - Pauline Brige
- Faculté de Médecine Timone (Aix-Marseille University), Marseille, France
| | - Sophie Chopinet
- Faculté de Médecine Timone (Aix-Marseille University), Marseille, France
| | | | | | | | | |
Collapse
|
35
|
Vidal V, Hak JF, Brige P, Chopinet S, Tradi F, Bobot M, Gach P, Haffner A, Soulez G, Jacquier A, Moulin G, Bartoli JM, Guillet B. In Vivo Feasibility of Arterial Embolization with Permanent and Absorbable Suture: The FAIR-Embo Concept. Cardiovasc Intervent Radiol 2019; 42:1175-1182. [PMID: 31025052 DOI: 10.1007/s00270-019-02211-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2018] [Accepted: 03/25/2019] [Indexed: 10/27/2022]
Abstract
PURPOSE Arterial embolization has been shown to be effective and safe for the management of bleeding, especially for postpartum and pelvic traumatic bleeding. We propose to evaluate the proof of concept of feasibility and effectiveness of arterial embolization with absorbable and non-absorbable sutures in a porcine model. MATERIALS AND METHODS In the acute setting (n = 1), several different arteries (mesenteric, splenic, pharyngeal, kidney) were embolized using non-absorbable sutures (NAS): Mersutures™ braided sutures (polyethylene terephthalate). In the chronic setting (n = 3), only lower pole renal arteries were embolized. On the right side, NAS was used, whereas on the left side embolization was realized with absorbable suture (AS): Vicryl® braided suture (polyglactin 910). The chronic group was followed for 3 months. The pigs received contrast-enhanced CT the day before embolization (D-1), after the embolization (D0), at 1 month and 3 months after embolization (M1 and M3); digital subtraction angiography (DSA) was done at D0 and M3 and histological analysis at M3. RESULTS All vascular targets were effectively embolized without any pre- or postoperative complications. Both DSAs and CTs at M3 showed a 100% recanalization rate for the AS embolization and a partial reversal rate for the NAS embolization. A renal hypotrophy in the embolized region was observed during both the M1 and M3 scans for both sutures (AS and NAS) with a clear hypotrophy for the NAS embolized kidney. CONCLUSION Embolization by AS and NAS (FAIR-Embo) is a feasible and effective treatment which opens up the possibility of global use of this inexpensive and widely available embolization agent.
Collapse
Affiliation(s)
- V Vidal
- Interventional Radiology Section, Department of Medical Imaging, University Hospital Timone APHM, Marseille, France. .,LIIE, Aix Marseille Univ, Marseille, France. .,CERIMED, Aix Marseille Univ, Marseille, France.
| | - J F Hak
- Interventional Radiology Section, Department of Medical Imaging, University Hospital Timone APHM, Marseille, France. .,LIIE, Aix Marseille Univ, Marseille, France. .,CERIMED, Aix Marseille Univ, Marseille, France.
| | - P Brige
- LIIE, Aix Marseille Univ, Marseille, France.,CERIMED, Aix Marseille Univ, Marseille, France
| | - S Chopinet
- LIIE, Aix Marseille Univ, Marseille, France.,CERIMED, Aix Marseille Univ, Marseille, France.,Department of Digestive Surgery, University Hospital Timone APHM, Marseille, France
| | - F Tradi
- Interventional Radiology Section, Department of Medical Imaging, University Hospital Timone APHM, Marseille, France.,LIIE, Aix Marseille Univ, Marseille, France.,CERIMED, Aix Marseille Univ, Marseille, France
| | - M Bobot
- CERIMED, Aix Marseille Univ, Marseille, France.,Department of Nephrology, University Hospital Conception APHM, Marseille, France.,INSERM 1263, INRA 1260, C2VN, Aix Marseille Univ, Marseille, France
| | - P Gach
- Interventional Radiology Section, Department of Medical Imaging, University Hospital Timone APHM, Marseille, France.,LIIE, Aix Marseille Univ, Marseille, France.,CERIMED, Aix Marseille Univ, Marseille, France
| | - A Haffner
- Department of Pathological Anatomy, University Hospital Timone APHM, Marseille, France
| | - G Soulez
- Department of Radiology, Centre Hospitalier de l'Université de Montréal, 1560 Sherbrooke East, Montreal, H2L 4M1, Canada
| | - A Jacquier
- Interventional Radiology Section, Department of Medical Imaging, University Hospital Timone APHM, Marseille, France
| | - G Moulin
- Interventional Radiology Section, Department of Medical Imaging, University Hospital Timone APHM, Marseille, France
| | - J M Bartoli
- Interventional Radiology Section, Department of Medical Imaging, University Hospital Timone APHM, Marseille, France
| | - B Guillet
- CERIMED, Aix Marseille Univ, Marseille, France.,INSERM 1263, INRA 1260, C2VN, Aix Marseille Univ, Marseille, France.,Department of Radiopharmacy, APHM, Marseille, France
| |
Collapse
|
36
|
Blin MG, Bachelier R, Fallague K, Moussouni K, Aurrand-Lions M, Fernandez S, Guillet B, Robert S, Foucault-Bertaud A, Bardin N, Blot-Chabaud M, Dignat-George F, Leroyer AS. CD146 deficiency promotes plaque formation in a mouse model of atherosclerosis by enhancing RANTES secretion and leukocyte recruitment. J Mol Cell Cardiol 2019; 130:76-87. [PMID: 30928429 DOI: 10.1016/j.yjmcc.2019.03.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/06/2018] [Revised: 02/26/2019] [Accepted: 03/25/2019] [Indexed: 11/18/2022]
Abstract
AIMS The progression of atherosclerosis is based on the continued recruitment of leukocytes in the vessel wall. The previously described role of CD146 in leukocyte infiltration suggests an involvement for this adhesion molecule in the inflammatory response. In this study, we investigated the role of CD146 in leukocyte recruitment by using an experimental model of atherogenesis. METHODS AND RESULTS The role of CD146 was explored in atherosclerosis by crossing CD146-/- mice with ApoE-/- mice. CD146 -/-/ApoE -/- and ApoE -/- mice were fed a Western diet for 24 weeks and were monitored for aortic wall thickness using high frequency ultrasound. The arterial wall was significantly thicker in CD146-deficient mice. After 24 weeks of Western diet, a significant increase of atheroma in both total aortic lesion and aortic sinus of CD146-null mice was observed. In addition, atherosclerotic lesions were more inflammatory since plaques from CD146-deficient mice contained more neutrophils and macrophages. This was due to up-regulation of RANTES secretion by macrophages in CD146-deficient atherosclerotic arteries. This prompted us to further address the function of CD146 in leukocyte recruitment during acute inflammation by using a second experimental model of peritonitis induced by thioglycollate. Neutrophil recruitment was significantly increased in CD146-deficient mice 12 h after peritonitis induction and associated with higher RANTES levels in the peritoneal cavity. In CD146-null macrophages, we also showed that increased RANTES production was dependent on constitutive inhibition of the p38-MAPK signaling pathway. Finally, Maraviroc, a RANTES receptor antagonist, was able to reduce atherosclerotic lesions and neutrophilia in CD146-deficient mice to the same level as that found in ApoE -/- mice. CONCLUSIONS Our data indicate that CD146 deficiency is associated with the upregulation of RANTES production and increased inflammation of atheroma, which could influence the atherosclerotic plaque fate. Thus, these data identify CD146 agonists as potential new therapeutic candidates for atherosclerosis treatment.
Collapse
Affiliation(s)
- Muriel G Blin
- Aix-Marseille Univ., INSERM 1263, INRA 1260, C2VN, Marseille, France
| | - Richard Bachelier
- Aix-Marseille Univ., INSERM 1263, INRA 1260, C2VN, Marseille, France
| | - Karim Fallague
- Aix-Marseille Univ., INSERM 1263, INRA 1260, C2VN, Marseille, France
| | - Karima Moussouni
- Aix-Marseille Univ., INSERM 1263, INRA 1260, C2VN, Marseille, France
| | - Michel Aurrand-Lions
- Aix Marseille Univ., CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Samantha Fernandez
- Aix-Marseille Univ., CERIMED, Secteur Nucléaire Pré-clinique, Timone, 13005 Marseille, France
| | - Benjamin Guillet
- Aix-Marseille Univ., INSERM 1263, INRA 1260, C2VN, Marseille, France; Aix-Marseille Univ., CERIMED, Secteur Nucléaire Pré-clinique, Timone, 13005 Marseille, France; Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France
| | - Stéphane Robert
- Aix-Marseille Univ., INSERM 1263, INRA 1260, C2VN, Marseille, France
| | | | - Nathalie Bardin
- Aix-Marseille Univ., INSERM 1263, INRA 1260, C2VN, Marseille, France; Assistance Publique-Hôpitaux de Marseille, Hôpital de la Conception, 13385 Marseille, France
| | | | - Françoise Dignat-George
- Aix-Marseille Univ., INSERM 1263, INRA 1260, C2VN, Marseille, France; Assistance Publique-Hôpitaux de Marseille, Hôpital de la Conception, 13385 Marseille, France
| | - Aurélie S Leroyer
- Aix-Marseille Univ., INSERM 1263, INRA 1260, C2VN, Marseille, France.
| |
Collapse
|
37
|
Lagier D, Tonon D, Garrigue P, Guillet B, Giacomino L, Martin JC, Alessi MC, Bruder N, Velly LJ. Thromboxane-prostaglandin receptor antagonist, terutroban, prevents neurovascular events after subarachnoid haemorrhage: a nanoSPECT study in rats. Crit Care 2019; 23:42. [PMID: 30744667 PMCID: PMC6371436 DOI: 10.1186/s13054-019-2338-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 01/31/2019] [Indexed: 12/12/2022]
Abstract
Background Several lipid metabolites in cerebrospinal fluid are correlated with poor outcomes in aneurysmal subarachnoid haemorrhage. Most of these metabolites bind to ubiquitous thromboxane–prostaglandin (TP) receptors, causing vasoconstriction and inflammation. Here, we evaluated terutroban (TBN), a specific TP receptor antagonist, for the prevention of post-haemorrhage blood-brain barrier disruption, neuronal apoptosis and delayed cerebral hypoperfusion. Methods The rat double subarachnoid haemorrhage model was produced by twice injecting (days 1 and 2) autologous blood into the cisterna magna. Seventy-eight male Sprague-Dawley rats were assigned to experimental groups. Rats exposed to subarachnoid haemorrhage were allocated to no treatment (SAH group) or TBN treatment by gastric gavage during the first 5 days after haemorrhage (SAH+TBN group). Control rats received artificial cerebrospinal fluid injections (CSF group). Sham-operated rats with or without TBN administration were also studied. Body weight and Garcia neurological scores were assessed on day 2 and day 5. We used nanoscale single-photon emission computed tomography (nanoSPECT) to measure brain uptake of three radiolabelled agents: 99mTechnetium-diethylenetriaminepentacetate (99mTc-DTPA), which indicated blood-brain barrier permeability on day 3, 99mTechnetium-annexin V-128 (99mTc-Anx-V128), which indicated apoptosis on day 4, and 99mTechnetium-hexamethylpropyleneamineoxime (99mTc-HMPAO), which indicated cerebral perfusion on day 5. Basilar artery narrowing was verified histologically, and cerebral TP receptor agonists were quantified. Results 99mTc-DTPA uptake unveiled blood-brain barrier disruption in the SAH group. TBN mitigated this disruption in the brainstem area. 99mTc-Anx-V128 uptake was increased in the SAH group and TBN diminished this effect in the cerebellum. 99mTc-HMPAO uptake revealed a global decreased perfusion on day 5 in the SAH group that was significantly counteracted by TBN. TBN also mitigated basilar artery vasoconstriction, neurological deficits (on day 2), body weight loss (on day 5) and cerebral production of vasoconstrictors such as Thromboxane B2 and Prostaglandin F2α. Conclusions Based on in vivo nanoscale imaging, we demonstrated that TBN protected against blood-brain barrier disruption, exerted an anti-apoptotic effect and improved cerebral perfusion. Thus, TP receptor antagonists showed promising results in treating post-haemorrhage neurovascular events.
Collapse
Affiliation(s)
- David Lagier
- Department of Anaesthesiology and Critical Care Medicine, University Hospital Timone, Marseille, France. .,C2VN Inserm 1263, Inra 1260, Aix Marseille University, Marseille, France.
| | - David Tonon
- Department of Anaesthesiology and Critical Care Medicine, University Hospital Timone, Marseille, France.,C2VN Inserm 1263, Inra 1260, Aix Marseille University, Marseille, France
| | - Philippe Garrigue
- CERIMED (European Center for Research in Medical Imaging), Aix Marseille University, Marseille, France
| | - Benjamin Guillet
- CERIMED (European Center for Research in Medical Imaging), Aix Marseille University, Marseille, France
| | - Laura Giacomino
- Department of Anaesthesiology and Critical Care Medicine, INT (Institut de Neurosciences de la Timone), University Hospital Timone, Aix Marseille University, Marseille, France
| | | | | | - Nicolas Bruder
- Department of Anaesthesiology and Critical Care Medicine, University Hospital Timone, Marseille, France
| | - Lionel J Velly
- Department of Anaesthesiology and Critical Care Medicine, INT (Institut de Neurosciences de la Timone), University Hospital Timone, Aix Marseille University, Marseille, France
| |
Collapse
|
38
|
Magalon J, Velier M, Simoncini S, François P, Bertrand B, Daumas A, Benyamine A, Boissier R, Arnaud L, Lyonnet L, Fernandez S, Dignat-George F, Casanova D, Guillet B, Granel B, Paul P, Sabatier F. Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis. Ann Rheum Dis 2019; 78:391-398. [PMID: 30612118 DOI: 10.1136/annrheumdis-2018-214218] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 10/31/2018] [Accepted: 11/16/2018] [Indexed: 12/11/2022]
Abstract
OBJECTIVE The autologous stromal vascular fraction (SVF) from adipose tissue is an alternative to cultured adipose-derived stem cells for use in regenerative medicine and represents a promising therapy for vasculopathy and hand disability in systemic sclerosis (SSc). However, the bioactivity of autologous SVF is not documented in this disease context. This study aimed to compare the molecular and functional profiles of the SVF-based medicinal product obtained from SSc and healthy subjects. METHODS Good manufacturing practice (GMP)-grade SVF from 24 patients with SSc and 12 healthy donors (HD) was analysed by flow cytometry to compare the distribution of the CD45- and CD45+ haematopoietic cell subsets. The ability of SVF to form a vascular network was assessed using Matrigel in vivo assay. The transcriptomic and secretory profiles of the SSc-SVF were assessed by RNA sequencing and multiplex analysis, respectively, and were compared with the HD-SVF. RESULTS The distribution of the leucocyte, endothelial, stromal, pericyte and transitional cell subsets was similar for SSc-SVF and HD-SVF. SSc-SVF retained its vasculogenic capacity, but the density of neovessels formed in SVF-loaded Matrigel implanted in nude mice was slightly decreased compared with HD-SVF. SSc-SVF displayed a differential molecular signature reflecting deregulation of angiogenesis, endothelial activation and fibrosis. CONCLUSIONS Our study provides the first evidence that SSc does not compromise the vascular repair capacity of SVF, supporting its use as an innovative autologous biotherapy. The characterisation of the specific SSc-SVF molecular profile provides new perspectives for delineating markers of the potency of SVF and its targets for the treatment of SSc.
Collapse
Affiliation(s)
- Jérémy Magalon
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France.,INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France
| | - Mélanie Velier
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France.,INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France
| | | | - Pauline François
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France.,INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France
| | - Baptiste Bertrand
- INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France.,Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France
| | - Aurélie Daumas
- Internal Medicine Department, Hôpital Nord & Hôpital de la Timone, AP-HM, Marseille, France
| | - Audrey Benyamine
- INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France.,Internal Medicine Department, Hôpital Nord & Hôpital de la Timone, AP-HM, Marseille, France
| | - Romain Boissier
- INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France.,Urology Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France
| | - Laurent Arnaud
- Vascular Biology Department, Hôpital de la Conception, AP-HM, Marseille, France
| | - Luc Lyonnet
- Vascular Biology Department, Hôpital de la Conception, AP-HM, Marseille, France
| | | | - Françoise Dignat-George
- INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France.,Vascular Biology Department, Hôpital de la Conception, AP-HM, Marseille, France
| | - Dominique Casanova
- Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France
| | - Benjamin Guillet
- INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France.,CERIMED, Aix-Marseille University, AP-HM, Marseille, France
| | - Brigitte Granel
- INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France.,Internal Medicine Department, Hôpital Nord & Hôpital de la Timone, AP-HM, Marseille, France
| | - Pascale Paul
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France.,INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France
| | - Florence Sabatier
- Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, Marseille, France .,INSERM, INRA, C2VN, Aix-Marseille University, Marseille, France
| |
Collapse
|
39
|
Muleki-Seya P, Payan C, Balasse L, Guillermin R, Roffino S, Guillet B, Franceschini E. Nonlinear ultrasound parameter to monitor cell death in cancer cell samples. J Acoust Soc Am 2018; 144:EL374. [PMID: 30522320 DOI: 10.1121/1.5066348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Accepted: 10/13/2018] [Indexed: 06/09/2023]
Abstract
A scaling subtraction method was proposed to analyze the radio frequency data from cancer cell samples exposed to an anti-cancer drug and to estimate a nonlinear parameter. The nonlinear parameter was found to be well correlated (R2 = 0.62) to the percentage of dead cells in apoptosis and necrosis. The origin of the nonlinearity may be related to a change in contacts between cells, since the nonlinear parameter was well correlated to the average total coordination number of binary packings (R2 ≥ 0.77). These results suggest that the scaling subtraction method may be used to early quantify chemotherapeutic treatment efficiency.
Collapse
Affiliation(s)
| | - Cédric Payan
- Aix-Marseille University, CNRS, Centrale Marseille, LMA, Marseille, France
| | - Laure Balasse
- Aix Marseille University, INSERM, VRCM, Marseille, France
| | - Régine Guillermin
- Aix-Marseille University, CNRS, Centrale Marseille, LMA, Marseille, France
| | - Sandrine Roffino
- Aix Marseille University, CNRS, ISM, Marseille, France , , , , , ,
| | | | | |
Collapse
|
40
|
Moyon A, Garrigue P, Balasse L, Fernandez S, Brige P, Nollet M, Hache G, Blot-Chabaud M, Dignat-George F, Guillet B. Early prediction of revascularisation by angiomotin-targeting positron emission tomography. Theranostics 2018; 8:4985-4994. [PMID: 30429881 PMCID: PMC6217063 DOI: 10.7150/thno.27728] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 08/10/2018] [Indexed: 12/11/2022] Open
Abstract
This study aimed to develop a PET imaging agent of angiomotin (AMOT) expression, a potential biomarker of functional tissue regeneration in post-ischaemic conditions. Methods: Hindlimb ischaemia was induced by ligature and resection of the right femoral artery in mice, and clinical score and limb perfusion were evaluated up to 30 days after surgery. AMOT expression was evaluated by histology and Western blot analysis. NODAGA-conjugates of AMOT ligand, sCD146, were designed, synthesised and radiolabelled with gallium-68. 68Ga-sCD146 microPET/CT imaging was performed from day 1 to day 30 after ischaemia. 68Ga-sCD146 specificity for AMOT was evaluated by autoradiography. Results: Immunohistochemistry showed a significant endothelial overexpression of AMOT from day 5 up to day 10 in the ischaemic hindlimb. 68Ga-sCD146 PET signal intensity correlated significantly with AMOT immunohistochemistry evaluation. 68Ga-sCD146 PET imaging showed a significant uptake in the ischaemic hindlimb from day 2 to day 15, peaking on day 5 (ipsi/contralateral ratio = 2.4 ± 1.3, P = 0.0005) and significantly decreased after pharmacological blocking (62.57 ± 11% decrease in PET signal P = 0.032). Finally, we observed a significant correlation between day 5 68Ga-sCD146 PET signal intensity and clinical recovery (day 28) or hindlimb perfusion recovery (day 30). Conclusions: This work reports for the first time an early and sustained increase in AMOT expression after hindlimb ischaemia in mice. We therefore developed an AMOT-targeting imaging agent, 68Ga-sCD146, and showed its specific uptake up to 21 days after ischaemic hindlimb using microPET imaging. Correlation of early post-ischaemic PET signal with both delayed perfusion recovery and clinical outcome allows us to postulate that 68Ga-sCD146 represents a promising radiotracer for tissue angiogenesis assessment.
Collapse
|
41
|
Bobot M, Hache G, Garrigue P, Brunet P, Burtey S, Guillet B. La scintigraphie rénale à l’acide dimercaptosuccinique 99mTc permet d’évaluer le développement de la fibrose interstitielle au cours d’un régime riche en adénine chez le rat. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Gabriel S, Garrigue P, Dahan L, Castinetti F, Sebag F, Baumstark K, Archange C, Jha A, Pacak K, Guillet B, Taïeb D. Prospective evaluation of 68 Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clin Endocrinol (Oxf) 2018; 89:155-163. [PMID: 29788534 PMCID: PMC7450718 DOI: 10.1111/cen.13745] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Revised: 05/10/2018] [Accepted: 05/17/2018] [Indexed: 12/21/2022]
Abstract
CONTEXT The 68 Ga-labelled somatostatin analogues (68 Ga-DOTA-SSAs) is becoming popular as an important diagnostic tool in neuroendocrine tumours as evidenced by a growing number of reports detailing institutional experience with various DOTA peptides. However, only few prospective studies have compared 68 Ga-DOTA-SSAs and somatostatin receptor scintigraphy (SRS) in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and pulmonary neuroendocrine tumours. OBJECTIVE The aim of our prospective study was to perform head-to-head comparison between 68 Ga-DOTATATE PET/CT and standard imaging work-up (SI) that included multiphasic CT, liver MRI and SRS using single photon emission computed tomography. DESIGN In this prospective study, the patients were enrolled only if they met any of the following inclusion criteria: (i) initial staging of a NETs without distant metastases on SI or neuroendocrine tumour with unknown primary on SI; (ii) restaging of NETs that could be treated by focused therapeutic interventions; (iii) elevated serum neuroendocrine hormones or peptides. The exclusion criteria was grade 3 GEP-NETs. RESULTS Thirty-two patients were enrolled in the study. Eleven patients (6 pancreas, 4 ileum, 1 duodenal) were included for initial evaluation and staging of NETs, 8 patients (5 pancreas, 1 ileal, 1 lung, 1 duodenal gastrinoma) for restaging, and 13 patients for elevated serum neuroendocrine biomarkers (5 ectopic Cushing's syndrome, 5 organic hypoglycaemia, 1 patient each with elevated vasoactive inhibitory peptide, chromogranin A and neuron-specific enolase). 68 Ga-DOTATATE PET/CT detected more primary tumours than SRS (15/18 vs 10/18: P = .074). The missed tumours on 68 Ga-DOTATATE PET/CT were located in the lung in two cases and duodenum in one case. For other anatomical regions (nodal and distant metastasis), no statistical difference was observed between imaging modalities using 68 Ga-DOTATATE PET/CT and SRS. Overall, 68 Ga-DOTATATE PET/CT+CT+MRI detected 31/33 of the involved regions (including primaries) (29 and 22 for 68 Ga-DOTATATE and SRS, respectively). CONCLUSION Our study shows that 68 Ga-DOTATATE PET/CT detected similar number of sites than combination of SRS, liver MRI and thoraco-abdominopelvic CT on region-based analysis. 68 Ga-DOTATATE PET/CT missed half of primary lung carcinoids with ectopic Cushing's syndrome.
Collapse
Affiliation(s)
- Sophie Gabriel
- Department of Nuclear Medicine, La Timone & North University Hospital, Aix-Marseille University, Marseille, France
- European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France
| | - Philippe Garrigue
- European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France
- Department of Radiopharmacy, La Timone & North University Hospital, Aix-Marseille University, Marseille, France
| | - Laetitia Dahan
- Digestive Oncology Unit, La Timone University Hospital, Aix-Marseille University, Marseille, France
| | - Frédéric Castinetti
- Department of Endocrinology, Conception Hospital, Aix-Marseille University, Marseille, France
| | - Frédéric Sebag
- Department of Endocrine Surgery, Conception Hospital, Aix-Marseille University, Marseille, France
| | - Karine Baumstark
- Department of Public Health, Aix-Marseille University, Marseille, France
| | - Cendrine Archange
- Department of Nuclear Medicine, La Timone & North University Hospital, Aix-Marseille University, Marseille, France
- European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France
| | - Abhishek Jha
- Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health, Bethesda, MD, USA
| | - Karel Pacak
- Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health, Bethesda, MD, USA
| | - Benjamin Guillet
- European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France
- Department of Radiopharmacy, La Timone & North University Hospital, Aix-Marseille University, Marseille, France
| | - David Taïeb
- Department of Nuclear Medicine, La Timone & North University Hospital, Aix-Marseille University, Marseille, France
- European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France
- Inserm UMR1068 Marseille Cancerology Research Center, Institut Paoli-Calmettes, Marseille, France
| |
Collapse
|
43
|
Brige P, Hery G, Palen A, Guilbaud T, Buffat C, Moyon A, Hardwigsen J, Guedj E, Guillet B, Vidal V, Gorincour G, Chopinet S, Gregoire E. Portal vein stenosis preconditioning of living donor liver in swine: early mechanisms of liver regeneration and gain of hepatic functional mass. Am J Physiol Gastrointest Liver Physiol 2018; 315:G117-G125. [PMID: 29470145 DOI: 10.1152/ajpgi.00390.2017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
To reduce the morbidity and mortality risk for the donor in living donor liver transplantation (LDLT), we previously identified 20% left portal vein (LPV) stenosis as an effective preconditioning method to induce cell proliferation in the contralateral lobe without downstream ipsilateral atrophy. In this study, we report the pathways involved in the first hours after preconditioning and investigate the changes in liver volume and function. Fourteen pigs were used this study. Five pigs were used to study the genetic, cellular and molecular mechanisms set up in the early hours following the establishment of our preconditioning. The remaining nine pigs were equally divided into three groups: sham-operated animals, 20% LPV stenosis, and 100% LPV stenosis. Volumetric scanning and 99 mTc-Mebrofenin hepatobiliary scintigraphy were performed before preconditioning and 14 days after to study morphological and functional changes in the liver. We demonstrated that liver regeneration triggered by 20% LPV stenosis in the contralateral lobe involves TNF-α, IL-6, and inducible nitric oxide synthase 2 by means of STAT3 and hepatocyte growth factor. We confirmed that our preconditioning was responsible for an increase in the total liver volume. Finally, we demonstrated that this volumetric gain was associated with an increase in hepatic functional capacity. NEW & NOTEWORTHY We describe a new preconditioning method for major hepatectomy that is applicable to hepatectomy for donation. We identified 20% left portal vein stenosis as effective preconditioning that is capable of inducing cell proliferation in the contralateral lobe without the downstream ipsilateral atrophy. In this study, we report the pathways involved in the first hours following preconditioning, and we confirm that 20% left portal vein stenosis is responsible for an increase in the functional capacity and total liver volume in a porcine model.
Collapse
Affiliation(s)
- Pauline Brige
- Experimental Interventional Imaging Laboratory EA-4264, European Centre for Medical Imaging Research, Aix-Marseille University , Marseille , France
| | - Geraldine Hery
- Experimental Interventional Imaging Laboratory EA-4264, European Centre for Medical Imaging Research, Aix-Marseille University , Marseille , France.,Department of General Paediatric Surgery, Hôpital de la Timone, Aix-Marseille University , Marseille , France
| | - Anais Palen
- Experimental Interventional Imaging Laboratory EA-4264, European Centre for Medical Imaging Research, Aix-Marseille University , Marseille , France.,Department of General Surgery and Liver Transplantation, Hôpital de la Timone, Aix-Marseille University , Marseille , France
| | - Théophile Guilbaud
- Experimental Interventional Imaging Laboratory EA-4264, European Centre for Medical Imaging Research, Aix-Marseille University , Marseille , France
| | - Christophe Buffat
- URMITE, CNRS UMR 6236-IRD 198, Aix-Marseille University, Marseille, France.,Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital de la Conception, Marseille , France
| | - Anais Moyon
- Vascular Research Center of Marseille, UMR-1076 INSERM, Aix-Marseille University , Marseille , France
| | - Jean Hardwigsen
- Department of General Surgery and Liver Transplantation, Hôpital de la Timone, Aix-Marseille University , Marseille , France
| | - Eric Guedj
- Nuclear Medicine, European Centre for Medical Imaging Research, Aix-Marseille University , Marseille , France
| | - Benjamin Guillet
- Vascular Research Center of Marseille, UMR-1076 INSERM, Aix-Marseille University , Marseille , France
| | - Vincent Vidal
- Experimental Interventional Imaging Laboratory EA-4264, European Centre for Medical Imaging Research, Aix-Marseille University , Marseille , France.,Department of Diagnostic and Interventional Imaging, Hôpital de la Timone, Aix-Marseille University , Marseille , France
| | - Guillaume Gorincour
- Experimental Interventional Imaging Laboratory EA-4264, European Centre for Medical Imaging Research, Aix-Marseille University , Marseille , France.,Department of Paediatric Diagnostic and Interventional Imaging, Hôpital de la Timone, Aix-Marseille University , Marseille , France
| | - Sophie Chopinet
- Department of General Surgery and Liver Transplantation, Hôpital de la Timone, Aix-Marseille University , Marseille , France
| | - Emilie Gregoire
- Experimental Interventional Imaging Laboratory EA-4264, European Centre for Medical Imaging Research, Aix-Marseille University , Marseille , France.,Department of General Surgery and Liver Transplantation, Hôpital de la Timone, Aix-Marseille University , Marseille , France
| |
Collapse
|
44
|
Essaadi A, Nollet M, Moyon A, Stalin J, Simoncini S, Balasse L, Bertaud A, Bachelier R, Leroyer AS, Sarlon G, Guillet B, Dignat-George F, Bardin N, Blot-Chabaud M. Stem cell properties of peripheral blood endothelial progenitors are stimulated by soluble CD146 via miR-21: potential use in autologous cell therapy. Sci Rep 2018; 8:9387. [PMID: 29925894 PMCID: PMC6010456 DOI: 10.1038/s41598-018-27715-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 05/21/2018] [Indexed: 12/27/2022] Open
Abstract
Cell-based therapies constitute a real hope for the treatment of ischaemic diseases. One of the sources of endothelial progenitors for autologous cell therapy is Endothelial Colony Forming Cells (ECFC) that can be isolated from peripheral blood. However, their use is limited by their low number in the bloodstream and the loss of their stem cell phenotype associated with the acquisition of a senescent phenotype in culture. We hypothesized that adding soluble CD146, a novel endothelial growth factor with angiogenic properties, during the isolation and growth procedures could improve their number and therapeutic potential. Soluble CD146 increased the number of isolated peripheral blood ECFC colonies and lowered their onset time. It prevented cellular senescence, induced a partial mesenchymal phenotype and maintained a stem cell phenotype by stimulating the expression of embryonic transcription factors. These different effects were mediated through the induction of mature miR-21. When injected in an animal model of hindlimb ischaemia, sCD146-primed ECFC isolated from 40 ml of blood from patients with peripheral arterial disease were able to generate new blood vessels and restore blood flow. Treatment with sCD146 could thus constitute a promising strategy to improve the use of autologous cells for the treatment of ischaemic diseases.
Collapse
Affiliation(s)
- Amel Essaadi
- Aix Marseille Univ, INSERM 1263, INRA 1260, C2VN, Marseille, France
| | - Marie Nollet
- Aix Marseille Univ, INSERM 1263, INRA 1260, C2VN, Marseille, France
| | - Anaïs Moyon
- Aix Marseille Univ, INSERM 1263, INRA 1260, C2VN, Marseille, France.,CERIMED (European Center of Research in Medical Imaging), Aix-Marseille University, Marseille, France
| | - Jimmy Stalin
- Aix Marseille Univ, INSERM 1263, INRA 1260, C2VN, Marseille, France
| | | | - Laure Balasse
- CERIMED (European Center of Research in Medical Imaging), Aix-Marseille University, Marseille, France
| | | | | | | | - Gabrielle Sarlon
- Service of Vascular Surgery, La Timone Hospital, Marseille, France
| | - Benjamin Guillet
- Aix Marseille Univ, INSERM 1263, INRA 1260, C2VN, Marseille, France.,CERIMED (European Center of Research in Medical Imaging), Aix-Marseille University, Marseille, France
| | | | - Nathalie Bardin
- Aix Marseille Univ, INSERM 1263, INRA 1260, C2VN, Marseille, France
| | | |
Collapse
|
45
|
Aidoud N, Delplanque B, Baudry C, Garcia C, Moyon A, Balasse L, Guillet B, Antona C, Darmaun D, Fraser K, Ndiaye S, Leruyet P, Martin JC. A combination of lipidomics, MS imaging, and PET scan imaging reveals differences in cerebral activity in rat pups according to the lipid quality of infant formulas. FASEB J 2018; 32:4776-4790. [DOI: 10.1096/fj.201800034r] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Nacima Aidoud
- Centre de Recherche Cardiovasculaire et Nutritionnelle (C2VN)INSERMInstitut National de la Recherche Agricole (INRA)BioMetMarseilleFrance
| | - Bernadette Delplanque
- Laboratoire de Neuroendocrinologie Moléculaire de la Prise Alimentaire (NMPA)Centre de Neurosciences Université Paris-Sud (CNPS)OrsayFrance
| | | | - Cyrielle Garcia
- Centre de Recherche Cardiovasculaire et Nutritionnelle (C2VN)INSERMInstitut National de la Recherche Agricole (INRA)BioMetMarseilleFrance
| | - Anais Moyon
- Centre Européen de Recherche en Imagerie Médicale (CERIMED)Université d'Aix-MarseilleMarseilleFrance
| | - Laure Balasse
- Centre Européen de Recherche en Imagerie Médicale (CERIMED)Université d'Aix-MarseilleMarseilleFrance
| | - Benjamin Guillet
- Centre Européen de Recherche en Imagerie Médicale (CERIMED)Université d'Aix-MarseilleMarseilleFrance
| | - Claudine Antona
- Centre de Recherche Cardiovasculaire et Nutritionnelle (C2VN)INSERMInstitut National de la Recherche Agricole (INRA)BioMetMarseilleFrance
| | - Dominique Darmaun
- INRAPhysiopathologie des Adaptations Nutritionnelles (PHAN)Université de NantesNantesFrance
- Thermo Fisher ScientificCourtaboeufFrance
| | - Karl Fraser
- Food Nutrition and Health TeamFood and Bio-Based Products GroupAgResearch Grasslands Research CentreRiddet InstituteMassey UniversityPalmerston NorthNew Zealand
| | - Sega Ndiaye
- INRAPhysiopathologie des Adaptations Nutritionnelles (PHAN)Université de NantesNantesFrance
- Thermo Fisher ScientificCourtaboeufFrance
| | | | - Jean-Charles Martin
- Centre de Recherche Cardiovasculaire et Nutritionnelle (C2VN)INSERMInstitut National de la Recherche Agricole (INRA)BioMetMarseilleFrance
| |
Collapse
|
46
|
Pinganaud C, Proulle V, Dreyfus M, Lambert T, Guillet B. Myocardial Infarction Occurring in a Case of Acquired Haemophilia During the Treatment Course with Recombinant Activated Factor VII. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1613284] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
47
|
Nollet M, Stalin J, Moyon A, Traboulsi W, Essaadi A, Robert S, Malissen N, Bachelier R, Daniel L, Foucault-Bertaud A, Gaudy-Marqueste C, Lacroix R, Leroyer AS, Guillet B, Bardin N, Dignat-George F, Blot-Chabaud M. A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule. Oncotarget 2017; 8:112283-112296. [PMID: 29348825 PMCID: PMC5762510 DOI: 10.18632/oncotarget.22736] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 11/14/2017] [Indexed: 12/20/2022] Open
Abstract
CD146 is an adhesion molecule present on many tumors (melanoma, kidney, pancreas, breast, ...). In addition, it has been shown to be expressed on vascular endothelial and smooth muscle cells. Generating an antibody able to specifically recognize CD146 in cancer cells (designated as tumor CD146), but not in normal cells, would thus be of major interest for targeting tumor CD146 without affecting the vascular system. We thus generated antibodies against the extracellular domain of the molecule produced in cancer cells and selected an antibody that specifically recognizes tumor CD146. This antibody (TsCD146 mAb) was able to detect CD146-positive tumors in human biopsies and in vivo, by PET imaging, in a murine xenograft model. In addition, TsCD146 mAb antibody was able to specifically detect CD146-positive cancer microparticles in the plasma of patients. TsCD146 mAb displayed also therapeutic effects since it was able to reduce the growth of human CD146-positive cancer cells xenografted in nude mice. This effect was due to a decrease in the proliferation and an increase in the apoptosis of CD146-positive cancer cells after TsCD146-mediated internalization of the cell surface CD146. Thus, TsCD146 mAb could be of major interest for diagnostic and therapeutic strategies against CD146-positive tumors in a context of personalized medicine.
Collapse
Affiliation(s)
- Marie Nollet
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| | - Jimmy Stalin
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| | - Anaïs Moyon
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France.,CERIMED, European Center of Research in Medical Imaging, Aix-Marseille University, Marseille, France
| | - Waël Traboulsi
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| | - Amel Essaadi
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| | - Stéphane Robert
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| | - Nausicaa Malissen
- Department of Dermatology, Timone Hospital, Assistance Publique des Hôpitaux de Marseille, Inserm UMR-S 911, Aix-Marseille University, Marseille, France
| | - Richard Bachelier
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| | - Laurent Daniel
- Service d'anatomie Pathologique, Aix-Marseille University, Timone Hospital, Marseille, France
| | | | - Caroline Gaudy-Marqueste
- Department of Dermatology, Timone Hospital, Assistance Publique des Hôpitaux de Marseille, Inserm UMR-S 911, Aix-Marseille University, Marseille, France
| | - Romaric Lacroix
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| | - Aurélie S Leroyer
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| | - Benjamin Guillet
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France.,CERIMED, European Center of Research in Medical Imaging, Aix-Marseille University, Marseille, France
| | - Nathalie Bardin
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| | | | - Marcel Blot-Chabaud
- INSERM UMR-S 1076, Aix-Marseille University, UFR Pharmacy, Marseille, France
| |
Collapse
|
48
|
Grandvuillemin I, Garrigue P, Ramdani A, Boubred F, Simeoni U, Dignat-George F, Sabatier F, Guillet B. Long-Term Recovery After Endothelial Colony-Forming Cells or Human Umbilical Cord Blood Cells Administration in a Rat Model of Neonatal Hypoxic-Ischemic Encephalopathy. Stem Cells Transl Med 2017; 6:1987-1996. [PMID: 28980775 PMCID: PMC6430056 DOI: 10.1002/sctm.17-0074] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Accepted: 07/26/2017] [Indexed: 02/06/2023] Open
Abstract
Neonatal hypoxic‐ischemic encephalopathy (NHIE) is a dramatic perinatal complication, associated with poor neurological prognosis despite neuroprotection by therapeutic hypothermia, in the absence of an available curative therapy. We evaluated and compared ready‐to‐use human umbilical cord blood cells (HUCBC) and bankable but allogeneic endothelial progenitors (ECFC) as cell therapy candidate for NHIE. We compared benefits of HUCBC and ECFC transplantation 48 hours after injury in male rat NHIE model, based on the Rice‐Vannucci approach. Based on behavioral tests, immune‐histological assessment and metabolic imaging of brain perfusion using single photon emission computed tomography (SPECT), HUCBC, or ECFC administration provided equally early and sustained functional benefits, up to 8 weeks after injury. These results were associated with total normalization of injured hemisphere cerebral blood flow assessed by SPECT/CT imaging. In conclusion, even if ECFC represent an efficient candidate, HUCBC autologous criteria and easier availability make them the ideal candidate for hypoxic‐ischemic cell therapy. Stem Cells Translational Medicine2017;6:1987–1996
Collapse
Affiliation(s)
- Isabelle Grandvuillemin
- Aix Marseille Univ, INSERM, VRCM, UMR_1076, UFR de Pharmacie, Marseille, France.,APHM, CHU La Conception, Department of Neonatology, Marseille, France
| | - Philippe Garrigue
- Aix Marseille Univ, INSERM, VRCM, UMR_1076, UFR de Pharmacie, Marseille, France.,APHM, Radiopharmacy, Marseille, France.,CERIMED, Aix Marseille Univ, Marseille, France
| | - Alaa Ramdani
- Aix Marseille Univ, INSERM, VRCM, UMR_1076, UFR de Pharmacie, Marseille, France
| | - Farid Boubred
- Aix Marseille Univ, INSERM, VRCM, UMR_1076, UFR de Pharmacie, Marseille, France.,APHM, CHU La Conception, Department of Neonatology, Marseille, France
| | - Umberto Simeoni
- Division of Pediatrics, CHUV & University of Lausanne, Switzerland
| | | | - Florence Sabatier
- Aix Marseille Univ, INSERM, VRCM, UMR_1076, UFR de Pharmacie, Marseille, France.,APHM, CHU La Conception, Cell Culture and Therapy Laboratory, INSERM CBT-1409, Marseille, France
| | - Benjamin Guillet
- Aix Marseille Univ, INSERM, VRCM, UMR_1076, UFR de Pharmacie, Marseille, France.,APHM, Radiopharmacy, Marseille, France.,CERIMED, Aix Marseille Univ, Marseille, France
| |
Collapse
|
49
|
Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ. Immunogenicity, efficacy and safety of Nuwiq®
(human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study. Haemophilia 2017; 24:211-220. [PMID: 28815880 DOI: 10.1111/hae.13320] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/05/2017] [Indexed: 01/19/2023]
Affiliation(s)
- R. J. Liesner
- Great Ormond Hospital for Children NHS Trust Haemophilia Centre; London UK
| | - M. Abashidze
- JSC Institute of Haematology and Transfusiology; Tbilisi Georgia
| | - O. Aleinikova
- Republican Scientific and Practical Centre of Children Oncology, Hematology and Immunology; Minsk Belarus
| | - C. Altisent
- Unitat d'Hemofilia; Hospital Vall D'Hebron; Barcelona Spain
| | - M. J. Belletrutti
- Pediatric Hematology; Department of Pediatrics; University of Alberta; Edmonton AB Canada
| | | | - M. Carcao
- Hospital for Sick Children; Toronto ON Canada
| | - H. Chambost
- Department of Pediatric Hematology Oncology; Children Hospital La Timone; APHM and Inserm; UMR 1062; Aix Marseille University; Marseille France
| | - A. K. C. Chan
- Division of Pediatric Hematology/Oncology; McMaster University; Hamilton ON Canada
| | - L. Dubey
- Western Ukrainian Specialized Children's Medical Centre; Lviv Ukraine
| | - J. Ducore
- Department of Pediatrics; UC Davis Medical Center; Sacramento CA USA
| | - N. A. Fouzia
- Christian Medical College Vellore; Vellore India
| | - M. Gattens
- Cambridge University Hospital NHS Foundation Trust; Cambridge UK
| | - Y. Gruel
- Hôpital Trousseau; Centre Régional de Traitement de l'Hémophilie; Tours France
| | - B. Guillet
- Haemophilia Treatment Centre of Rennes-Brittany; University Hospital of Rennes; Rennes France
| | - N. Kavardakova
- National Children's Specialized Clinic “OHMATDET”; Kiev Ukraine
| | - M. El Khorassani
- Centre de traitement de l'hémophilie; University Mohamed V; Rabat Morocco
| | | | - T. Lambert
- CRTH Hôpital Universitaire Bicêtre APHP; Le Kremlin Bicêtre France
| | - S. Lohade
- Sahyadri Speciality Hospital; Pune India
| | - M. Sigaud
- Centre Régional de Traitement de I'Hémophilie; University Hospital of Nantes; Nantes France
| | - V. Turea
- Scientific Research Institute of Mother and Child Health Care; Chişinău Moldova
| | - J. K. M. Wu
- B.C. Children's Hospital; Vancouver BC Canada
| | - V. Vdovin
- Morozovskaya Children's Hospital; Moscow Russia
| | - A. Pavlova
- Institute of Experimental Haematology and Transfusion Medicine; University Clinic Bonn; Bonn Germany
| | - M. Jansen
- Octapharma Pharmazeutika Produktionsges.mbH; Vienna Austria
| | | | | | - S. Knaub
- Octapharma AG; Lachen Switzerland
| | - E. J. Neufeld
- St. Jude Children’s Research Hospital; Memphis TN USA
| |
Collapse
|
50
|
Garrigue P, Bodin-Hullin A, Balasse L, Fernandez S, Essamet W, Dignat-George F, Pacak K, Guillet B, Taïeb D. The Evolving Role of Succinate in Tumor Metabolism: An 18F-FDG-Based Study. J Nucl Med 2017; 58:1749-1755. [PMID: 28619735 DOI: 10.2967/jnumed.117.192674] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 05/24/2017] [Indexed: 12/27/2022] Open
Abstract
In recent years, inherited and acquired mutations in the tricarboxylic acid (TCA) cycle enzymes have been reported in diverse cancers. Pheochromocytomas and paragangliomas often exhibit dysregulation of glucose metabolism, which is also driven by mutations in genes encoding the TCA cycle enzymes or by activation of hypoxia signaling. Pheochromocytomas and paragangliomas associated with succinate dehydrogenase (SDH) deficiency are characterized by high 18F-FDG avidity. This association is currently only partially explained. Therefore, we hypothesized that accumulation of succinate due to the TCA cycle defect could be the major connecting hub between SDH-mutated tumors and the 18F-FDG uptake profile. Methods: To test whether succinate modifies the 18F-FDG metabolic profile of tumors, we performed in vitro and in vivo (small-animal PET/CT imaging and autoradiography) experiments in the presence of succinate, fumarate, and phosphate-buffered saline (PBS) in different cell models. As a control, we also evaluated the impact of succinate on 18F-fluorocholine uptake and retention. Glucose transporter 1 (GLUT1) immunohistochemistry was performed to assess whether 18F-FDG uptake correlates with GLUT1 staining. Results: Intratumoral injection of succinate significantly increased 18F-FDG uptake at 24 h on small-animal PET/CT imaging and autoradiography. No effect of succinate was observed on cancer cells in vitro, but interestingly, we found that succinate caused increased 18F-FDG uptake by human umbilical vein endothelial cells in a concentration-dependent manner. No significant effect was observed after intratumoral injection of fumarate or PBS. Succinate, fumarate, and PBS have no effect on cell viability, regardless of cell lineage. Intramuscular injection of succinate also significantly increases 18F-FDG uptake by muscle when compared with either PBS or fumarate, highlighting the effect of succinate on connective tissues. No difference was observed between PBS and succinate on 18F-fluorocholine uptake in the tumor and muscle and on hind limb blood flow. GLUT1 expression quantification did not significantly differ between the study groups. Conclusion: The present study shows that succinate stimulates 18F-FDG uptake by endothelial cells, a finding that partially explains the 18F-FDG metabotype observed in tumors with SDH deficiency. Although this study is an 18F-FDG-based approach, it provides an impetus to better characterize the determinants of 18F-FDG uptake in various tumors and their surrounding microenvironment, with a special emphasis on the role of tumor-specific oncometabolites.
Collapse
Affiliation(s)
- Philippe Garrigue
- Aix-Marseille University, INSERM, UMR-S 1076, Marseille, France.,Aix-Marseille University, CERIMED, Marseille, France.,Department of Nuclear Medicine, Aix-Marseille University, Marseille, France
| | | | - Laure Balasse
- Aix-Marseille University, INSERM, UMR-S 1076, Marseille, France.,Aix-Marseille University, CERIMED, Marseille, France
| | | | - Wassim Essamet
- Department of Neuropathology, APHM Timone, Marseille, France; and
| | | | - Karel Pacak
- Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland
| | - Benjamin Guillet
- Aix-Marseille University, INSERM, UMR-S 1076, Marseille, France.,Aix-Marseille University, CERIMED, Marseille, France.,Department of Nuclear Medicine, Aix-Marseille University, Marseille, France
| | - David Taïeb
- Aix-Marseille University, CERIMED, Marseille, France .,Department of Nuclear Medicine, Aix-Marseille University, Marseille, France
| |
Collapse
|